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1.INTRODUCTION 
        (Yie WC.,1992; Rawlins EA.,1992; Lachman L.)
          
1.1 Introduction to tablets:                                   
 
For many decades, treatment of acute disease or a chronic illness has been mostly 
accomplished by delivery of drugs to patients using various pharmaceutical dosage forms 
including tablets, capsules, pills, suppositories, creams, ointments, liquids, aerosols and 
injectables as drug carriers.                                               
Drug may be administered by variety of routes but oral administration is adopted 
wherever possible. It is safest, easiest and most economical route of drug administration.
 
Among the drugs that are administered orally solid oral dosage forms i.e. tablets and capsules 
represent the preferred class of products.                 
 
Solid medicaments may be administered orally as powders, pills, cachets, capsules   
or tablets. These dosage forms contain a quantity of drug which is given as a single unit     
and they are known collectively as solid unit dosage forms, even in the case of sustained       
action preparations which, technically contain the equivalent of several normal doses of   
drug. The stringent formulation requirements of modern medicaments, the many     
advantages of tablet and capsule medication, coupled with expanding health services and    
the commitment need for large-scale economic manufacture, have led to a steady decline in 
the prescribing of powders and pills. Tablets and capsules on the other hand, currently 
account for well over two third of the total number and cost of medicines produced all over 
the world.  
Tablet is defined as a compressed solid dosage form containing medicaments with    
or without excipients. According to the Indian Pharmacopoeia Pharmaceutical tablets are 
solid, flat or biconvex dishes, unit dosage form, prepared by compressing a drugs or a 
mixture of drugs, with or without diluents. They vary in shape and differ greatly in size      
and weight, depending on amount of medicinal substances and the intended mode of 
administration. It is the most popular dosage form and 70% of the total medicines are  
dispensed in the form of Tablet. All medicaments are available in the tablet form except 
where it is difficult to formulate or administer.  
BILAYER TABLETS OF SUMATRIPTAN SUCCINATE                                                CHAPTER-1 
 
 
ADHIPARASAKTHI COLLEGE OF PHARMACY  2 
 
1.1.1 Advantages and disadvantages of tablets as dosage forms 
         (AultonM, Loyd V. Allen) 
Tablets are the most popular dosage form used today and therefore there are several 
advantages associated with their use. However it is also important to highlight the 
disadvantages associated with their use. 
Advantages 
 Tablets are convenient to use and are an elegant dosage form. 
 A wide range of tablet types is available, offering a range of drug release rates and 
durations of clinical effect. Tablets may be formulated to offer rapid drug release or 
controlled drug release, the latter reducing the number of daily doses required (and    
in so doing increasing patient compliance). 
 Tablets may be formulated to release the therapeutic agent at a particular site      
within the gastrointestinal tract to reduce side effects, promote absorption at that     
site and provide a local effect (e.g. ulcerative colitis). This may not be easily    
achieved by other dosage forms that are administered orally. 
 Tablets may be formulated to contain more than one therapeutic agent (even if     
there is a physical or chemical incompatibility between each active agent).    
Moreover, the release of each therapeutic agent may be effectively controlled by     
the tablet formulation and design. 
 With the exception of proteins, all classes of therapeutic agents may be     
administered orally in the form of tablets. 
 It is easier to mask the taste of bitter drugs using tablets than for other dosage      
forms, e.g. liquids. 
 Tablets are generally an inexpensive dosage form. 
 Tablets may be easily manufactured to show product identification, e.g. exhibiting   
the required markings on the surface. 
 The chemical, physical and microbiological stability of tablet dosage forms is  
superior to other dosage forms. 
Disadvantages 
 The manufacture of tablets requires a series of unit operations and therefore there is 
an increased level of product loss at each stage in the manufacturing process. 
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 The absorption of therapeutic agents from tablets is dependent on physiological 
factors, e.g. gastric emptying rate. 
 The compression properties of certain therapeutic agents are poor and may present 
problems in their subsequent formulation and manufacture as tablets. 
 The administration of tablets to certain groups, e.g. children and the elderly may be 
problematic due to difficulties in swallowing. These problems may be overcome by 
using effervescent tablet dosage forms. 
 1.1.2 Properties of an ideal tablet: 
The objective of formulation and fabrication of tablet is to deliver the correct amount of    
drug in proper form at or over proper time. 
 Tablet should be elegant having its own identity and free from defects such as    
cracks, chips, contamination, discoloration etc. 
 It should have chemical and physical stability to maintain its physical integrity over 
time. 
 It should be capable to prevent any alteration in the chemical and physical         
properties of medicinal agents.   
 It should be capable of withstanding the rigors of mechanical shocks encountered      
in its production, packaging, shipping and dispensing. 
 An ideal tablet should be able to release the medicaments in body in predictable     
and reproducible manner.  
1.1.3 Different types of Tablets                  (Dr P.K. Sahoo) 
(A) Tablets ingested orally:  
1. Compressed tablet, e.g. Paracetamol tablet  
2. Multiple compressed tablet ` 
3. Repeat action tablet  
4. Delayed release tablet, e.g. Enteric coated Bisacodyl tablet  
5. Sugar coated tablet, e.g. Multivitamin tablet  
6. Film coated tablet, e.g. Metronidazole tablet  
7. Chewable tablet, e.g. Antacid tablet  
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(B) Tablets used in oral cavity:  
1. Buccal tablet, e.g. Vitamin-c tablet  
2. Sublingual tablet, e.g. Vicks Menthol tablet  
3. Troches or lozenges  
4. Dental cone  
(c) Tablets administered by other route:  
1. Implantation tablet  
2. Vaginal tablet, e.g. Clotrimazole tablet 
(D) Tablets used to prepare solution:  
1. Effervescent tablet, e.g. Dispirin tablet (Aspirin)  
2. Dispensing tablet, e.g. Enzyme tablet (Digiplex)  
3. Hypodermic tablet  
4. Tablet triturates e.g. Enzyme tablet (Digiplex)  
 Compressed tablets: Standard uncoated tablets are manufactured by compression. 
The general methods are by wet granulation, dry granulation or direct compression, 
used for rapid disintegration and drug release. Both type of action – systemic effect 
and local effect.  
 Multiple compressed tablets: For incompatible components these are:  
Layered tablet:- Either two layered (for two components) or three layered (for three 
components) tablet.  
Compressed coated type:- Either tablet within a tablet or tablet within a tablet      
within a tablet. Tablet in this category are usually prepared for two reasons  
o To separate physically or chemically incompatible ingredients.  
o To produce repeat action or prolong action product.  
 Repeat action tablet: Sugar coated or multiple compressed tablets are used for this 
purpose .The core tablet is usually coated with shellac or an enteric polymer so that    
it will not release its drug in stomach but intestine.  
 Delayed action and enteric-coated tablet: This dosage form is intended to release 
the drug after some time delay or after the tablet has passed one part of the GIT      
into another. All enteric coated tablets are type of delayed action tablet but all    
delayed action tablets are not enteric or not intended to produce enteric action.  
 Sugar coated tablet: Primary role is to produce an elegant, glossy, easy to      
swallow, widely utilized in preparing multivitamin and multivitamin mineral 
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combination. Sugar coating doubled the tablet weight. Now polymers are used with 
sugar solution.  
 Film coated tablet: One type of coated tablet in which drug is not required in 
coating. This is an attractive method within one or two hours. Polymers such as 
hydroxypropylcellulose, hydroxypropylmethyl cellulose, and colloidal dispersion     
of ethylcellulose are commonly used. A 30% dispersion of ethyl cellulose is known  
as aquacoat. Advantage of film coated over sugar coated tablets is better       
mechanical strength and flexibility of the coating, little increase in tablet weight.  
 Chewable tablet: These are intended to be chewed in the mouth before      
swallowing. Used for large tablet of antacid, bitter or foul testing drugs are not 
suitable for this type tablet.  
 Buccal and sublingual tablet: These tablets are small, flat and are intended to be 
held between the cheek and teeth or in cheek pouch (buccal tablet) or below the 
tongue (sublingual tablet). Drugs used by this route are for quick systematic action. 
The tablets are designed not to be disintegrated but slowly dissolve.  
 Troches and lozenges: Used in the oral cavity to exert local effect in mouth and 
throat. They are commonly used to treat sore throat or to control coughing in    
common cold. They may contain local anaesthetics, antiseptic, antibacterial agents, 
demulcents, astringent and antitussive. The tablets are dissolving slowly             
over a period of 30 minutes.  
 Dental cone: These tablets are designed to be placed in the empty socket       
remaining after tooth extraction. Main purpose is to prevent microbial growth in       
the socket or to reduce bleeding.  
 Implantation tablets: designed for substances implantation to provide prolonged 
drug effect from one month to a year, tablets are usually small, cylindrical not more 
than 8mm length. These methods require special surgical technique for       
implantation and discontinuation of therapy. Generally used for administration of 
growth hormone to food producing animal.  
 Vaginal tablets: These are designed to undergo slow dissolution and drug release     
in vaginal cavity. Tablets are wide or pear shaped, used to antibacterial, antiseptic    
and astringent to treat vaginal infection.  
 Effervescent tablets: Tablets are designed to produce a solution rapidly with the 
release of carbon dioxide. The tablets are prepared by compressing the active 
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ingredient with mixture of organic acid such as citric acid or tartaric acid and     
sodium bicarbonate.  
 Dispersing tablets: Tablets are intended to be added to a given volume of water to 
produce a solution of a given drug concentration.  
 Hypodermic tablets: These tablets are composed of one or more drugs with water-
soluble ingredients. Drug is added to sterile water to prepare sterile solution, which    
is injectable.  
 Tablet triturates: Usually are made from moist materials using a triturate mold, 
which gives them the shape of cylinder. Such tablet must be completely and rapidly 
soluble. 
 1.2 Techniques to formulate the tablets       
                                                               (Bentley’s, Larry L. Augsburger, Bogner RH.,1997) 
Normally tablets are manufactured by any one of the following methods. 
 Direct compression 
 Granulation 
1.2.1 Direct compression:  
 The process of direct compression is a process of applying pressure via an     
upper and a lower punch to materials held in die cavity without doing any prior granulation 
processes. 
                    A compressible vehicle is blended with the medicinal agent, and if necessary, 
with a lubricant and a disintegrant, and then the blend is compressed. Substances that are 
commonly used as directly compressible vehicles are: Lactose, Dicalcium phosphate 
(Emcompress), Spray Dried Mannitol (Pearlitol SD 200), Microcrystalline Cellulose 
(Avicel), compressible sugar (Di-Pac), Starch (Sta-Rx 1500), Hydrolyzed Starch (Celutab), 
and a blend of Sugar, Invert sugar, Starch and Magnesium stearate (Nutab). 
The following statements are considered main advantages of direct compression 
method: 
o Single process, because the critical steps like granulation, drying or not involved. 
o Thermoliabile and moisture sensitive drug can be used in this technique, in which it 
can’t be done in granulation method. 
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o Energy and cost of manufacturing is less comparative to granulation method. 
o Faster dissolution was obtained. 
The following statements are considered disadvantages of direct compression method: 
o Tablet weight, thickness, hardness uniformity is difficult to achieve. 
o Segregation of drug and excipient may occur. 
o For the low dose tablets required content uniformity is difficult to achieve. 
 
Table 1: General Direct Compression Tablet formula 
 
 
1.2.2 Granulation              (Loyd V. Allen) 
 Its part of the pharmaceutical process that attempts to improve the flow of      
powdered materials by forming spheres like aggregates called granules. 
a) Dry granulation 
 In the dry methods of granulation the primary powder particles are aggregated      
under high pressure and no liquid is used. 
b) Wet granulation 
Tabletting by wet granulation process is the most widely used method for 
pharmaceutical materials. The technique involves a number of stages. During the 
development of a tablet formulation, all the physical variables that affect the resultant 
granules have to be also considered to maximize the quality of the final product. 
           Wet granulation involves the massing of a mix of dry primary powder particles     
using a granulating fluid. The fluid contains a solvent, which must be volatile, so that it      
can be removed by drying and it must be non-toxic. 
Active Pharmaceutical Ingredient 0.1-99% 
Filler-binder 
(Dependent on API loading 
and compactability) 
1-99% 
Disintegrant 0.5-2% 
Lubricant 0.5-2% 
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Typical liquids of Aqueous (or) Non Aqueous Solvents can be used alone or in 
combination. 
The granulation agents may be used alone or usually as a solvent containing a 
dissolved solvent in turn containing a dissolved adhesive (also referred to as binder (or) 
binding agent) which is used to ensure particle adhesion when the granule is dry. 
1.3 Tablet Ingredients                                     (Dr P.K. Sahoo) 
In addition to active ingredients, tablet contains a number of inert materials known as 
additives or excipients. Different excipients are:  
1. Diluent  
2. Binder and adhesive  
3. Disintegrants  
4. Lubricants and glidants  
5. Colouring agents  
6. Flavouring agents  
7. Sweetening agents  
1.3.1. Diluent: Diluents are fillers used to make required bulk of the tablet when the drug 
dosage itself is inadequate to produce the bulk. Secondary reason is to provide better tablet 
properties such as improve cohesion, to permit use of direct compression manufacturing or    
to promote flow. A diluent should have following properties:  
1. They must be non toxic  
2. They must be commercially available in acceptable grade  
3. There cost must be low  
4. They must be physiologically inert  
5. They must be physically & chemically stable by themselves & in combination with the 
drugs.  
6. They must be free from all microbial contamination.  
7. They do not alter the bioavailability of drug.  
8. They must be colour compatible.  
Commonly used tablet diluents  
1. Lactose-anhydrous and spray dried lactose  
2. Directly compressed starch-Sta Rx 1500  
3. Hydrolyzed starch-Emdex and Celutab  
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4. Microcrystalline cellulose-Avicel (PH 101and PH 102)  
5. Dibasic calcium phosphate dehydrate  
6. Calcium sulphate dihydrate  
7. Mannitol  
8. Sorbitol  
9. Sucrose- Sugartab, DiPac, Nutab  
10. Dextrose  
Lactose: Most widely used diluent in tablet formulation. Lactose has no reaction with       
most drugs, whether it is used in hydrous or anhydrous form. Anhydrous lactose has 
advantage over lactose that it does not undergo Maillard reaction which is browning & 
discoloration of tablet due to the interaction of amine drug with lactose. Spray dried       
lactose in conc 20-25% of active ingredient is used for direct compression.  
Starch obtained from corn, wheat, potatoes is used as diluent, Sta-Rx 1500 is free flowing, 
direct compressible starch used as diluent, binder and /or disintegrating agent. Two 
hydrolyzed starch Emdex and Celutab, which are combination of 90-92% of dextrose and    
3-5% of maltose, are free flowing and direct compressible.  
Sucrose is used as diluent. Some sugar-based diluents are used for direct compression.    
These are:  
a) Sugartab: 90-93% sucrose and 7-10% invert sugar  
b) DiPac: 97%sucrose and 3% modified dextrin  
c) Nu Tab: 95%sucrose & 4% invert sugar with small amount of corn starch & magnesium 
stearate.  
Microcrystalline cellulose, having trade name Avicel is used for direct      
compression. These are two types: PH101 (Powder) and PH102 (Granules). Dibasic     
calcium phosphate and calcium sulphate used as diluents but reduce bioavailability of 
tetracycline tablet.  
1.3.2. Binders and Adhesives: These materials are added either dry or in wet- form to     
form granules or to form cohesive compacts for directly compressed tablet.  
Example: Acacia, tragacanth- Solution for 10-25% Conc.  
Cellulose derivatives- Methyl cellulose, Hydroxypropyl methyl cellulose, Hydroxypropyl 
cellulose  
Gelatin- 10-20% solution  
Glucose- 50% solution  
Polyvinylpyrrolidone (PVP)- 2% conc.  
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Starch paste-10-20% solution  
Sodium alginate  
Sorbitol  
1.3.3. Disintegrants: Added to a tablet formulation to facilitate its breaking or     
disintegration when it contact in water in the GIT.  
Example: Starch- 5-20% of tablet weight.  
Starch derivative – Primogel and Explotab (1-8%)  
Clays- Veegum HV, bentonite 10% level in colored tablet only  
Cellulose derivatives- Ac- Di-Sol (sodium carboxy methyl cellulose)  
Alginate  
PVP (Polyvinylpyrrolidone), cross-linked  
Super disintegrants: Swells up to ten fold within 30 seconds when contact water.  
Example: Croscarmellose- cross-linked cellulose, Crosspovidone- cross-linked povidone 
(polymer), Sodium starch glycolate- cross-linked starch. These cross-linked products swell 
upto 10 fold within 30 seconds when in contact with water.  
A portion of disintegrant is added before granulation and a portion before compression, 
which serve as glidants or lubricant. Evaluation of carbon dioxide in effervescent tablets is 
also one way of disintegration  
1.3.4. Lubricant and Glidants: Lubricants are intended to prevent adhesion of the tablet 
materials to the surface of dies and punches, reduce inter particle friction and may improve 
the rate of flow of the tablet granulation.  
Glidants are intended to promote flow of granules or powder material by reducing the    
friction between the particles.  
Example: Lubricants- Stearic acid, Stearic acid salt - Stearic acid, Magnesium stearate,     
Talc, PEG (Polyethylene glycols), Surfactants  
Glidants- Corn Starch – 5-10% conc., Talc-5% conc., Silica derivative - Colloidal silicas   
such as Cab-O-Sil, Syloid, Aerosil in 0.25-3% conc.  
1.3.5. Colouring agent: The use of colours and dyes in a tablet has three purposes:  
(1) Masking of off colour drugs  
(2) Product Identification  
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(3) Production of more elegant product  
All colouring agents must be approved and certified by FDA. Two forms of colours are     
used in tablet preparation – FD &C and D & C dyes. These dyes are applied as solution in   
the granulating agent or Lake form of these dyes. Lakes are dyes absorbed on hydrous    
oxide and employed as dry powder colouring.  
Example: FD & C yellow 6-sunset yellow  
FD & C yellow 5- Tartrazine  
FD & C green 3- Fast Green  
FD & C blue 1- Brilliant Blue  
FD & C blue 2 - Indigo carmine  
D & C red 3- Erythrosine 
D & C red 22 – Eosin Y  
1.3.6. Flavouring agents: For chewable tablet- flavour oil are used.  
1.3.7. Sweetening agents: For chewable tablets: Sugar, mannitol.  
Saccharine (artificial): 500 times sweeter than sucrose  
Disadvantage: Bitter aftertaste and carcinogenic  
Aspartame (artificial)  
Disadvantage: Lack of stability in presence of moisture.  
       (Darshana HD.,2000; Turner S.,2004; Chien YW.,2010) 
The goal of any drug delivery system is to provide a therapeutic amount of drug to   
the proper site of the body, to achieve promptly and then maintain the desired therapeutic 
drug concentration that elicits the desired pharmacological actions and to minimize the 
incidence and the severity of unwanted adverse effects. To achieve this goal, it would be 
advantageous and more convenient to maintain a dosing frequency to once, or at most, a 
twice-daily regimen. An appropriately designed extended release dosage form can be a    
major advance in this direction compared to conventional immediate release dosage forms. 
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A large number of preparations deliver drugs in immediate release form that are 
absorbed in the upper regions of the small intestine, an increasingly important group of 
products frequently referred to as modified, controlled, or extended-release delivery     
systems are designed to deliver drug in the entire gastrointestinal (GI) tract but always in a 
controlled manner. The common rationale underpinning all systems is to modulate the 
magnitude and duration of drug action and to dissociate or modify these from the inherent 
limitations and properties of the drug molecules.
  
In recent times, various developed and developing countries move towards 
combination therapy for treatment of multiple diseases and disorders requiring long term 
therapy such as hypertension and diabetes. Combination therapy have various advantages 
over monotherapy such as problem of dose dependent side effects is minimized, a low      
dose of two different agents reduces the dose related risk, the addition of one agent may 
potentiate effects of other agent. Using low dosage of two different agents minimizes the 
clinical and metabolic side effects that occur with maximal dosage of individual      
component of the combined tablet and thus dose of the single components can be reduced. 
Bilayer tablets are novel drug delivery systems where combination of two or more drugs in 
single unit having different release profiles improves patient compliance, prolongs the     
drugs action, avoid saw tooth kinetics resulting in effective therapy along with better    
control of plasma drug level. Bilayer tablets are very common dosage form for drugs such    
as captopril, metoprolol, amoxicillin and potassium clavanate, propanolol hydrochloride, 
bambuterol hydrochloride. Joint national committee VI recognized the value of     
combination therapy and suggested that combining drugs with different modes of action      
will often allow smaller doses of drugs to be used to achive control and minimize the           
potential dose dependent side effects. JNCvi recomended  that the combination of a low    
dose of two drugs in fixed dose combination  is an appropriate choice for initial treatment    
of any chronic disease. Hence management of multiple diseases can be effectively and     
better done by bilayer tablet or layering tablet. 
1.4 Layered tablet:                (Lieberman HA.,2008; Cremer K.,2001) 
 Layer tablet is composed of two or three layers of granulation compressed together. 
They have appearance like as sandwich because the edges of each layer are exposed. This 
dosage form has the advantage of separating two incompatible substances with an inert 
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barrier between them. Layer tablet may be bilayer, trilayer or multilayer depending up on the 
number of layers. 
1.4.1 Multi layer tablets:  
 This tablet consists of two or more layers of materials compressed successively in the 
same tablets. The colour of each layer may be the same or different. The tablets having   
layers of different colours are known as multicoloured tablets. 
 Multilayer tablets are the tablets made by compressing several different      
granulations fed into a die in succession, one on top of another, in layers. Each layer comes 
from a separate feed frame with individual weight control. Rotary tablet presses can be    
setup for two or three layers. More are possible but the design become very special.      
Ideally, a slight compression of each layer and individual layer ejection permits weight 
checking for control purposes. 
1.4.2 Advantage of multilayer tablets:  
 This dosage form has the advantage of separating two incompatible substances      
with an inert barrier between them.  
It makes possible sustained-release preparations with the immediate-release quantity in      
one layer and the slow release proportion in the second. A third layer, with an immediate 
release might be added. 
 The weight of each layer can be accurately controlled, in contrast to putting one     
drug of a combination product in a sugar coating. Two layer tablets require fewer materials 
than compression coated tablets, weigh less, and may be thinner. Monograms and other 
distinctive markings may be impressed in the surface of the multilayer tablets. Colouring     
the separate layer provides many possibilities for unique tablet identity. Analytical work     
may be simplified by the separation of layer prior to assy. Since there is no transfer to a 
second set of punches and dies, as with the dry coating machine, odd shapes (such as    
triangle, squares, and ovals) present no operating problems except for those common to 
keyed tooling. 
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1.4.3 Problems in layered tablets: 
 Lack of proper bonding of two layers. 
 Stress due to high compression force degrades certain actives, e.g; ramipril. 
1.4.4 Bilayer tablets:                    (Lachman.,2008) 
Bilayer tablets are prepared with one layer of drug for immediate release while     
second layer designed to release drug later, either as second dose or in an extended release 
manner. Bilayer tablet is suitable for sequential release of two drugs in combination,     
separate two incompatible substances, and also for sustained release tablet in which one   
layer is immediate release as initial dose and second layer is maintenance dose. 
1.4.5 Applications:  
1. Used in combination therapy. 
2. Used to deliver the loading dose and sustained dose of the same or different drugs. 
3. Used for bilayer floating in which one layer is floating layer another one is release 
layer of the drug. 
4. Used to deliver the two different drugs having different release profiles. 
1.4.6 Advantages: 
1. Bilayer tablet is suitable for preventing direct contact of two drugs and thus two 
maximize the efficacy of combination of two drugs. 
2. Patient compliance is enhanced leading to improve drug regimen efficacy. 
3. Patient convenience is improved because fewer daily doses are required compared    
to traditional delivery system. 
4. Bilayer tablets can be designed in such a manner as to modify releases as either of   
the layers can be kept as extended and the other as immediate release. 
5. Fixed low-dose combinations are very useful tools for treatment. 
1.4.7 Disadvantages:  
1. Adds complexity and bilayer rotatary presses are expensive. 
2. Insufficient hardness, layer separation, reduced yield. 
3. Inaccurate individual layer weight control. 
4. Cross-contamination between the layers. 
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1.4.8 Ideal properties for bilayer tablet press: 
1. Preventing capping and separation of the two individual layers that constitute the 
bilayer tablet. 
2. Preventing cross-contamination between the two layers. 
3. Producing a clear visual separation between the two layers. 
4. High yield, accurate and individual weight control of the two layers. 
1.4.9 Types of bilayer tablet press: 
1. Single sided tablet press. 
2. Double sided tablet press. 
3. Bilayer tablet press with displacement monitoring. 
 
1. Single sided tablet press:  The simplest design is a single sided press with both 
chambers of the doublet feeder separated from each other. Each chamber is gravity    
or forced fed with different power, producing the two individual layers of tablets. 
When die passes under the feeder, it is first loaded with the first layer powder 
followed by the second layer powder. Then the entire tablet is compressed in one or 
two steps. 
Limitations of the single sided press: 
1. No weight monitoring / control of the individual layers. 
2. No distinct visual separation between the two layers. 
3. Very short first layer dwell time due to the small compression roller, possibly 
resulting in poor de-aeration, capping and hardness problems. 
4. This may be corrected by reducing the turrent-rotation speed (to extend the   
dwell time) but with the consequence of lower tablet output. 
      2. Double sided tablet press: In most double sided tablet presses with automated    
production control use compression force to monitor and control tablet weight. The 
effective peak compression force exerted on each individual force exerted on each 
individual tablet or layer is measured by the control system at main compression of 
the layer. This measured peak compression force is the signal used by the control 
system to reject out of tolerance and correct the die fill depth when required. 
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  3.  Bilayer tablet press with displacement: The displacement tablet weight control 
principle is fundamentally different from the principle based upon compression    
force. When measuring displacement, the control system sensitivity does not      
depend on the tablet weight but depends on the applied precompression force. 
 1.4.10 SIZES AND SHAPES:              (Banker G) 
               Size is limited by the capacity of the machine with the total thickness being the 
same as a single-layer tablet. Many shape other than round or possible and or limited only    
by the ingenuity of the die maker. However, deep concavities can cause distoriation of the 
layers. Therefore standard concave and flat-face beveled edge tooling make for the best 
appearance, especially when the layers are of different colours. 
1.4.11 GRANULATIONS: 
                For a good- quality tablets with sharp definition between the layers, special care 
must be taken as follows… 
• Dusty fines must be limited. Fines smaller than 100 mesh should be kept at a    
minimum 
• Maximum granule size should be less than 16 mesh for smooth, scrape –off at the die  
• Materials that smear chalk, or coat on the die table must be avoided to obtain clean 
scrape-off and uncontaminated layers. 
• Low moisture is essential if incompatibilities are used. 
• Weak granules that break down easily must be avoided. Excessive amounts of 
lubrication, especially metallic stearates, should be avoided for better adhesion of the 
layers. 
• Formulation of bi layer tablets is more demanding than the single-layer tablets. For    
this reason selection of additives is critical.  
 1.5 TABLET BILAYER PRESS 
         A Tablet bi-layer press is simply a tablet press that has been modified so that it has     
two die-filling and compression cycles for each revolution of the press. In short, each      
punch compresses twice, once for the first layer of a two-layer tablet and a second time for 
the second layer. Three-layer presses are equipped with three such compression cycles. 
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           There are two types of layer presses presently in use-one in which each layer can be 
ejected from the press separately for the purpose of weight checking, and the second in    
which the first layer is compressed so hard that the second layer will not bond to it, or will 
bond so poorly that upon ejection the layers easily separated for weighing. Once the proper 
weight adjustments have been made by adjusting the die fill, the pressure is adjusted to the 
proper tablet hardness and bonding of the layers. 
         One hazard of layer tablet production is the lack of proper bonding of the layers. This 
can result in a lot of 100,000, tablets ending up as 200,000 layers after several days if the 
layers are not sufficiently bonded. 
      In a two-layer tablet press, two hopers above the rotary die table feed granulated    
material to two separate feed frames without intermixing. Continuous, gentle circulation      
of  the materials through hoppers  and feed frames assures uniform filling without  
segregation   of particle sizes that would otherwise carry over to the second layer and      
affect the layer weight ,tablet hardness, and, in case of differently coloured granulations ,    
the appearance of the tablet. The same procedure is followed in the three layer press with 
three hoppers for the granulations instead of two. 
     Certain single layer or unit tablet presses are equipped with two compression station    
prior to the final compaction. These high speed productions by increasing dwell time of the 
material under pressure make tablets harder and denser. 
1.5.1 CONVENTIONAL TECHNIQUES FOR PREPARATION OF BILAYERED 
TABLETS:                  (Banker G) 
Bi layered tablets can be prepared by the following methods: 
 Tablet moulding 
 Direct compression 
 Spray drying 
 Sublimation 
 Freeze drying (or) Lyophilization 
 Mass extrusion 
 Taste masking 
 Use of sugar based excipients 
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1) Tablet Moulding: 
 Moulded tablets are usually prepared by different moulding techniques. 
A. Compression moulding: The powder mixture previously moistened with a   
solvent like ethanol/water is compressed into mould plates to form a wetted mass. 
B. Heat moulding: The moulded forms can be obtained directly from a molten    
matrix in which the drug is dispersed / dissolved. 
C. No vacuum Lyophilization: In this process at standard pressure the solvent     
from a drug solution or suspension is evaporated. 
 Tablets produced by moulding are solid dispersion. Moulded tablets disintegrate   
more rapidly and offer improved taste because the dispersion matrix is in general made    
from water soluble sugars. The active ingredients in most cases are absorbed through the 
mucosal lining of the mouth. The tablets prepared by moulding offer more rapid 
disintegration and improved taste as the dispersion matrix is made from water soluble 
excipients (sugars). 
 Moulded tablets typically do not possess great mechanical strength. Erosion and 
breakage of the moulded tablet often occur during handling and opening of blister packs. 
2)  Direct Compression  
 It is the easiest way to manufacture tablets with low cost, conventional equipments, 
commonly available excipients and a limited number of processing steps leading to this 
technique is preferable one. High doses can be accommodated and final weight of tablet      
can easily exceed that of other production methods. 
 The disintegration and dissolution of directly compressed tablets depend on single    
or combined effect of disintegrate, water soluble excipients and effervescing agents. The 
optimum concentration of superdisintegrant can be selected according to critical 
concentration of the disintegrate. Below this concentration the tablet disintegration time is 
inversely proportional to the concentration of superdisintegrant, whereas if concentration     
of superdisintegrant incorporated in tablet is above the critical concentration, the 
disintegration time remains approximately constant or even increases. 
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3)  Spray Drying  
 Spray drying technique produces highly porous and fine powders as the processing 
solvent is evaporated during the process. This technique is based upon a particulate       
support matrix that is prepared by spray drying an aqueous composition containing support 
matrix and other components to form a highly porous and fine powder. This is then mixed 
with active ingredient and compressed into tablet, which disintegrated in less than 20    
seconds     when immersed in an aqueous medium. 
4)  Sublimation 
 Compressed tablets composed of water soluble excipients as tablet matrix often do    
not dissolve rapidly due to low porosity. Bi layer tablets having porous structure and 
sufficient mechanical strength, which dissolves quickly have been developed using urea, 
ammonium carbonate, camphor, naphthalene, and tablet excipients and finally compressed 
the blend. Porous structure is generated by sublimation of volatile oil. 
5)  Freeze Drying / Lyophilization  
 A process in which water is sublimated from the product after freezing is called 
Freeze drying. Lyophilization results in preparations which are highly porous with a very 
high specific surface area, which dissolve rapidly and show improved absorption and 
bioavailability. 
 The use of Freeze drying is limited due to high cost of the equipment and      
processing. Other major disadvantages of the final dosage forms include lack of physical 
resistance in standard blister packs. 
6)  Mass Extrusion 
 This technology involves softening the active blend using the solvent mixture of   
water soluble polyethylene glycol, using methanol and expulsion of softened mass through 
the extruder or syringe to get a cylinder of the product into even segments using heated    
blade to form tablets. The dried cylinder can also be used to coat granules of bitter tasting 
drugs and thereby masking their bitter taste. 
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7)  Taste Masking 
 Taste masking is an essential requirement for bi layer Tablets for commercial   
success. Drugs with unacceptable bitter taste can be microencapsulated into pH sensitive 
acrylic polymers like Eudragit E, Eudragit L-55 and Eudragit RL. 
8)   Use of Sugar Based Excipients  
 Sugar based excipients (eg: Sorbitol, mannitol, dextrose, xylitol, fructose etc.) have 
been used as bulk agents. Aqueous solubility and sweetness impart pleasing mouth feel       
and good taste masking. But no sugar based materials have fast dissolution rate and good 
compressibility and/or compatibility. However technologies are developed to make use of   
the sugar based excipients in the design of bi layer tablet. 
1.5.2 Potential reason for considering the double-layer dosage form: 
 One of the most common reasons that have developed for wishing to manufacture 
double-layer product centres on sustained release verses immediate release active     
ingredients and the related bioavailability of each within the human body. It is the      
intention of the manufacturer in some cases to formulate products that utilize two different 
actives, one whose pharmacological effect is available to the body shortly after it is      
ingested (immediate release) and another that fulfils its route more slowly over a long     
period of time (sustain release). These two functions can be neatly delivered in the same 
tablet by separating the actives into two distinct layers. Some active ingredient     
combinations for a tablet may also be better suited to the double layer form if they cannot 
easily be blended in to the same final formulation. Certain ingredient may simply need to     
be physically separated due to incompatibility. An example of a characteristic that might 
foster such incompatibility would be disparate dissolution rates. 
 Another modern catalyst for utilization of the double-layer form focuses on the      
idea of product line extension. As patent protection begins to wane manufacturers can 
sometimes breathe a new life into a product line by modifying its format or presentation.   
This can in some cases be achieved by creating a double-layer version of what was 
historically in mono-layer tablet. The best cases may result in a new patent for the revised 
form, there by extending the life of a product line. 
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 Perhaps the most interesting emerging use for a double-layer tablet focuses on the 
desire to thwart abuse of a constituent ingredient. Abusers of pharmaceutical preparation 
have been increasingly successful and inventive in their ability to extract powerful     
ingredient for use not intended by the manufacture. 
 Certain new painkillers, for example, provide wonderful benefits to a patient in      
need who uses them according to the manufacturer instructions. When an abuser      
mishandles them, however, they can become dangerous and potentially addictive. The  
makers of some of this type of products are beginning to investigate the use of double-    
layer forms, where an antagonist layer is formulated in such a way as to foil would be 
abuser’s attempt to extract the active ingredient that they are seeking it abuse. 
1.5.3 Solving incompatibility problem: 
 Not only active ingredients but also excipients may cause incompatibility either    
with other excipients or with the drug, and thus lead to unsatisfactory product stability.     
They preferred strategy to avoid such undesirable interaction is to reformulate the product 
using other excipients rather than designing a layer tablet. 
 Drug-drug interactions leading to incompatibility are rare. However, even if the 
problem occurs, it is usually solved by using other strategies, such as isolating one of the 
drugs by micro encapsulation prior to its incorporation, or by developing hard gelatin 
capsules which contain two species of pellets with different drugs. 
 Nevertheless, some products also use layer tablets for the same purpose. One of the 
most successful formulations of these types is the popular American multivitamin product, 
Dual Tabs, which contains vitamins in one of its two layers, and mineral salts, betaine, and 
glutamic acid, some of which would accelerate the decomposition of the vitamins, in the 
other. 
1.5.4 Some novel bilayer and trilayer tablet devices:  
(Patra CN.,2007; Sonara GS.,2007; Ohmori S.,2000; Li B.,2007; Fassihi R.,1997;) 
A. Sustained release bilayer tablets: 
The multilayered tablet concept has been long utilized to develop sustained release 
formulations. Such a tablet has a fast releasing layer and may contain bi-or triple layers to 
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sustain the drug release. The pharmacokinetic advantage relies on the fact that drug release 
from fast releasing granules lead to a sudden rise in the blood concentration. However, the 
blood level is maintained at steady state as the drug is released from the sustaining granule. 
Among the different polymers, Eudragit and ethylcellulose have been used successfully to 
obtain appropriate sustained release matrix formulations of different materials. 
B. Bilayer and floating-bioadhesive tablets: 
 A bilayer and floating-bioadhesive drug delivery system exhibiting a unique 
combination of floatation and bioadhesion to prolong residence in the stomach. The   
sustained layer was compressed and granules of the floating layer were added to it then    
both layers were compressed using a single station rotator press. Granules and tablets were 
characterized using a official method. The kind of the tablet exhibits independent     
regulation of buoyancy and drug release.  
C. Bilayer caplets: 
 A bilayer caplets are excellent in two respect; firstly, single unit, such as bilayer 
caplets, excel in unit size than multiple unit, such as spansule capsules, and secondly,      
tablet shape changes from flat to capsule-like, namely caplets, that improves easiness in 
swallowing as compared with flat tablets.  
D. Tablet in capsule devices: 
 This novel system is so called tablet in capsule devices. The designed capsule      
device consists of an impermeable capsule body and a soluble cap. The multi-layered 
formulation prepared is filled within the capsule body and sealed with the water-soluble     
cap. Three-layered tablets, which serves as the first two pulses, a two-layered tablet or in 
powdered forms, which forms the pulsatile drug release. Both multi-layered tablets are 
inserted into an impermeable capsule body with a water soluble cap, lactose filled in the 
bottom.  
E. Three layered tablet system: 
 To allow biphasic drug release a three-layer tablet system has been developed. Two 
layers both contain a drug dose. An outer drug layer contains the immediately available    
dose of drug. An intermediate, made of swellable polymers, separates the drug layers. A    
film of an impermeable polymer coats the layer containing the other dose of drug. The first 
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layer can also involve a drug-free hydrophilic polymer barrier providing delayed (5h) drug 
absorption.  
1.5.5 Bilayer problems:                    (Vogeleer J.,2002) 
 Layer separation. 
 Insufficient hardness. 
 Inaccurate individual layer weight control. 
 Cross contamination between layers. 
 Reduced yield. 
1.5.6 Bi-layer tablets: Quality and GMP-requirement:  
 To produce a quality bi-layer tablet, in a validated and GMP-way, it is important      
that the selected press is capable of: 
 Preventing capping and separation of the two individual layers that constitute the 
bilayer tablet. 
 Providing sufficient tablet hardness. 
Preventing cross-contamination between the two layers. 
 High yield. 
 Accurate and individual weight control of the two layers. 
1.6 MIGRAINE:              (D.K Arulmozhi.,2005; Stephen D.,2006) 
Migraine is a chronic, often debilitating disease that affects 12% of the general 
population. This episodic brain disorder is characterized by unilateral throbbing headache 
lasting from 4 h to 3 days. Associated symptoms include nausea vomiting and sensitivity       
to light, sound and head movements.
 
A working definition of migraine is benign recurring 
headache and/or neurological dysfunction usually attended by pain-free interludes and      
often provoked by stereotyped stimuli. Migraine is more common in females, with a 
hereditary predisposition towards attacks and the cranial circulatory phenomenon appears     
to be secondary to a primary central nervous system disorder.
 
Migraine apparently a global 
disorder, occurring in all races, cultures and geographical locations. Current figures     
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suggest that 18% of women and six percent of men suffer from migraine and those      
numbers are increasing. The highest incidence of migraine occurs between the ages of 20    
and 35 and often associated with a positive family history of the disease.
 
 
Migraine is a common episodic pain disorder, the treatment of which can be acute     
to stop an attack or preventive to reduce the frequency, duration or severity of attacks. 
Preventive treatment is used when attacks are frequent or disabling. Many different 
medication groups are used for preventive treatment, including β-blockers, antidepressants 
and antiepileptic drugs. Their mechanisms of action include raising the threshold to    
migraine activation, enhancing antinociception, inhibiting cortical spreading depression, 
inhibiting peripheral and central sensitization, blocking neurogenic inflammation and 
modulating sympathetic, parasympathetic or 5-HT tone. In this article, I review evidence     
of the effectiveness of migraine preventive drugs. I also discuss the setting of treatment 
priorities.
  
1.6.1 Pathophysiology of migraine:         (D.K Arulmozhi.,2005) 
Migraine is characterized by episodes of head pain that is often throbbing and 
frequently unilateral and may be severe. In migraine without aura (previously known as 
common migraine) attacks are usually associated with nausea, vomiting, or sensitivity to 
light, sound, or movement and when treated, the attacks typically last 4 to 72 h. A 
combination of features is required for the diagnosis, but not all features are present in     
every attack or in every patient. These symptoms do distinguish migraine from tension      
type headache, the most common form of primary headache, which is characterized by the 
lack of associated features. Any severe and recurrent headache is most likely a form of 
migraine and should be responsive to antimigraine therapy. In 15% of patients migraine 
attacks are usually preceded or accompanied by transient focal neurotic symptoms, which    
are usually visual; such patients have migraine with aura (previously known as classic 
migraine). In a recent, large population-based study, 64% of patients with migraine had    
only migraine without aura, 18% had only migraine with aura and 13% had both types of 
migraine (the remaining 5% had aura without headache). Thus, up to 31% of patients with 
migraine have aura on some occasions, but clinicians who rely on the presence of aura for    
the diagnosis of migraine will miss many cases. A recent survey by the World Health 
Organization(WHO), rates severe migraine, along with quadriplegia, psychosis, and 
dementia, as one of the most disabling chronic disorders. This ranking suggests that in the 
judgment of WHO, a day with severe migraine is a disabling as a day with quadriplegia. 
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 1.6.2 Theories of migraine: 
 a) Vascular theory 
In the late 1930’s, Harold Wolff became the first researcher to place migraine on a 
scientific basis, Wolf measured the diameter of the extracranial (temporal) arteries in     
patients suffering migraine attacks and found them to be dilated. These patients were    
treated with vasoconstrictors (ergotamine) which relieved the pain and decreased the     
arterial dilation. Although subsequent events leading to headache (and associated     
symptoms) are not completely understood, the increased vascular pulsation may activate 
stretch receptors. This would, in turn increase the activity of neuropeptide containing    
(mainly calcitonin gene-related peptide (CGRP) perivascular nerves which may ultimately 
cause pain and other associated symptoms.  In line with the finding that carotid   
arteriovenous anastomoses dilatation play a role in the pathogenesis of migraine, it is 
reasonable to believe that compounds which produce a cranioselective vasoconstriction    
may have a potential therapeutic use in the treatment of migraine. In anaesthetized dogs     
and pigs acutely acting antimigraine drugs, ergot alkaloids (ergotamine and 
dihydroergotamine) and triptans (sumatriptan and second generation triptans) produced 
potent vasoconstriction in the canine and porcine carotid vasculature. Further studies 
demonstrated that mainly 5-HT1B receptors mediate sumatriptan- induced cranial 
vasoconstriction, involving carotid arteriovenous anastomoses and temporal and middle 
meningeal arteries. 
 b) Neurological theory 
A second theory of migraine is the neurological theory of migraine. This theory 
suggests that migraine arises as a result of abnormal neuronal firing and neurotransmitter 
release in brain neurons. This theory focuses on an explanation for certain symptoms, such   
as premonitory symptoms occurring prior to an attack (prodrome), which are difficult to 
explain based on the vascular hypothesis. The fact that migraine headaches begin and    
develop slowly coupled to the fact that external factors, such as stress, and hunger can 
precipitate migraine attacks to pathologies arising in the neuronal system, thus supporting      
a neurological basis of migraine. Cortical spreading depression, an expanding     
depolarization of cortical neurons which is well characterized in many species but not in    
man is often suggested to underlie the aura or prodrome associated with initiation of    
migraine attack. During spreading depression, cortical function is disrupted subsequent to 
neuronal depolarization and increased extracellular potassium. These cortical changes are 
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thought to be the cause of the transient sensory or motor impairments that frequently     
proceed the painful period of a migraine attack. 
c) Neurogenic theory: 
  In this it demonstrated that blood flow changes similar to those known to occur in 
migraine could be produced by electrically stimulating brain stem structures. This finding    
led to the neurogenic theory. Stimulation studies investigated the relationship between the 
trigeminal nerve and the cranial vasculature showed that trigeminovascular axons from     
blood vessels of the pia mater and dura mater release vasoactive peptides producing a     
sterile    inflammatory reaction with pain. During this neurogenic inflammation, the 
trigeminal ganglion is stimulated and this induces neurogenic protein extravasation. 
Vasodilatory peptides then released, including calcitonin gene related peptide (CGRP), 
substance P (SP) and neurokinin A. Neurogenic theory is an attempt to reconcile the    
vascular changes in the neuronal dysfunction that may occur in migraine headache and 
proposes that migraine pain is associated with inflammation and dilation of the meninges, 
particularly the dura, a membrane surrounding the brain. Neurogenic dural inflammation is 
thought to result from the actions of inflammatory neuropeptides released from the      
primary sensory nerve terminals innervating the dural blood vessels. In fact, the dural 
membrane surrounding the brain is the source for the majority of intracranial pain afferents 
and dural stimulation produces headache like pain in human. Stimulation or inflammation    
of sensory fibers release the inflammatory neuropeptides, substance P and calcitonin gene-
related peptide onto dural tissue, where these peptides produce a local response called 
neurogenic inflammation. Neurogenic inflammation may lower the nociceptive threshold 
required to stimulate meningial sensory fibers. According to neurogenic dural      
inflammation theory of migraine, release of these inflammatory neuropeptides in the dura 
mater during migraine can act on vascular tissues to cause vasodilatation, plasma protein 
extravasation in the surrounding area, endothelial changes, platelet aggregation and 
subsequent release of serotonin and other mediators, white cell adhesion and subsequent 
inflammation. CGRP plays a facilitatory role in this process. Whereas substance P induces 
extravasation via activation of NK1 receptors, release of CGRP enhances the effects of 
substance P by increasing dural blood flow and by inhibiting an extracellular enzyme that 
normally can metabolize substance P. Therefore, these two sensory neuropeptides act in 
concert to produce painful dural inflammation. Although not reliably demonstrated,    
increased cranial venous concentration of CGRP have been observed during a migraine   
attack and the elevated concentrations of CGRP have returned to normal following    
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treatment of the   migraine in the serotonergic agonists. This theory is in consistent with the 
proposal that serotonergic agonist alleviate the acute pain of migraine by inhibiting the 
release of substance P and CGRP from trigeminal sensory afferent neurons surrounding      
the meninges. 
1.6.4 Pain mechanisms in migraine: 
The pathogenesis of pain in migraine is not completely understood so far, but three 
key factors merit considerations are: the cranial blood vessels, the trigeminal innervation      
of the vessels, and the reflex connection of the trigeminal system in the cranial 
parasympathetic outflow. The substance of the brain is largely insensate; pain can be 
generated by large cranial vessels, proximal intracranial vessels or by the dura mater.      
These vessels are innervated by branches of the ophthalmic division of the trigeminal     
nerve, whereas the structures of the posterior fossa are innervated by branches of the C2 
nerve roots. In nonhuman primates, stimulation of vascular afferents leads to the activation   
of neurons in    the superficial layers of the trigeminal nucleus caudalis in the region of the 
craniomedullary junction and the superficial layers of the dorsal horns C1 and C2 levels of 
the spinal cord trigeminocervical complex. Similarly, stimulation of branches of C2    
activates neurons in the same regions of the brain. The involvement of ophthalmic division   
of the trigeminal nerve and the overlap with structures innervated by C2 explain the     
common distribution of migraine pain over the frontal and temporal regions, as well as 
involvement of parietal, occipital and high cervical regions by what is, in essence, referred 
pain. Peripheral trigeminal activation in migraine is evidenced by release of CGRP, a 
vasodilator,  but the mechanism of generation of pain is not clear. Studies in animals     
suggest that the pain may be caused by a sterile neurogenic inflammatory process in the    
dura mater, but this mechanism has not been clearly demonstrated to correlate in humans. 
The pain may be a combination of an altered perception as a result of peripheral or central 
sterilization of craniovascular input that is not usually painful and the activation of feed-
forward neurovascular dilator mechanism that is functionally specific for the first 
(ophthalmic) division of the trigeminal nerve. 
 
1.6.5 Emerging therapies        (Peterson K.A., 2005; Edvinsson., 2004; Goldstein 
D.J.,1999) 
a) Calciotonin gene-related peptide (CGRP) antagonists: 
In the recent past, there has been an upsurge in CGRP research and its notable role    
in migraine pathophysiology. As discussed above, migraine headache is closely associated 
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with the activation of trigeminovascular system. CGRP immunoreactive fibres originating    
in the trigeminal ganglion innervate cranial cerebral blood vessels. In animals, stimulation   
of these sensory nerve fibers has been shown to cause antidromic release of CGRP and 
subsequent vasodilatation in the cerebral vasculature. Plasma concentrations of CGRP in    
the jugular venous blood, but not of other neuropeptides were elevated during the      
headache phase of migraine. Furthermore, in migraine patients: (a) strong correlation was 
found between plasma CGRP concentrations and migraine headache (b) infusion of CGRP 
produced a migraine-like headache (c) baseline CGRP levels were considerably higher and 
(d) the changes in plasma CGRP levels during migraine attacks significantly correlated     
with the headache intensity. Hence, inhibition of CGRP or antagonism of CGRP receptors 
could be a viable therapeutic target for the pharmacological treatment of migraine. In line 
with this concept, an important breakthrough in the field of CGRP is the development of 
potent CGRP receptor antagonist olcegepant (BIBN4096BS). In the in vivo animal models   
of migraine, olcegepant attenuated the vasodilation induced by trigeminal stimulation and 
capsaicin- induced anastomotic dilatation. Data from recently published clinical proof-of-
concept study by demonstrated the effectiveness and safety of olcegepant for acute     
treatment of migraine, in which the response rate was found similar to oral triptans. No 
cardiovascular side effects have been reported following administration of olcegepant. The 
lack of cardiovascular side effects may prove to be a major advantage for using CGRP 
receptor antagonists to treat migraine. 
b) Anticonvulsants: 
Migraine and epilepsy share several features and respond too many of the same 
pharmacological agents suggesting similar mechanism may be involved in their 
pathophysiology, hence new targets are being investigated for the prophylactic therapy of 
migraine. Amongst these, anticonvulsants as a class of drugs hold promise for the migraine 
prophylaxis. These drugs are thought to act through multiple mechanisms involving      
voltage gated ion channels, ligand gated ion channels, GABA (g- amino butyric acid), 
glutamate etc. In the central nervous system, GABA is a major inhibitory neurotransmitter 
and known anticonvulsant drugs like sodium valproate, topiramate and gabapentine have 
been shown to be effective in preventing migraine through modulation of GABA 
neurotransmission. 
c) Histamine H3 agonists: 
In recent study, histamine H3 agonists are evaluated for the safety and efficacy for 
migraine prophylaxis. Hence carefully controlled doses of H3 receptor 
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agonist may offer an alternative approach to migraine prophylaxis. 
d) Botulinum toxin type A: 
BoNT-A, produced by the bacterium Clostridium botolinium consists of a heavy 
chain and light chain linked by a disulfide bond. BoNT-A binds to pre-synaptic nerve 
terminal and is internalized into the cell, where it inhibits acetylcholine release by     
interfering with vesicle docking. These effects make BoNT-A useful for the treatment of 
many disorders related to excessive muscle contraction, such as strabismus,      
blepharospasm, hemifacial spasm and cervical dystonia. New applications of BoNT-A in   
pain therapy support a mechanism for pain reduction that is more complex than a simple 
secondary effect of muscle relaxation. BoNT-A has been used successfully to treat several 
different types of headaches, including tension type headaches. cervicogenic headaches      
and migraine. Although some types of headaches may have been relieved by the inhibition    
of muscle contraction at trigger points, the efficacy of BoNT-A in treating migraine    
headache implies a direct action on sensory neurons, with an indirect central action. It is 
believed that release of vasoactive neuropeptides, such as SP and CGRP from the     
trigeminal nerve onto the vasculature produces vasodilatation and plasma protein 
extravasation due to increased permeability of post capillary venules. It is proposed that,     
the effectiveness of BoNT-A for the treatment of migraine in the clinical setting may be     
due to its inhibition of neurogenic inflammation induced by the peripheral release of SP      
and CGRP. 
e) Coenzyme Q10: 
There has been recent interest in the role that mitochondria may play in migraine 
pathogenesis. It is clear from the recent studies that at least a subset of migraineurs has a 
dysfunction in mitochondrial energy metabolism. Coenzyme Q10 is an essential element      
of the mitochondrial electron transport chain. It is naturally occurring, small hydrophobic 
substance that freely moves throughout the membrane transferring electrons from the    
NADH dehydrogenase complex and the succinate-Q-reductase complex to cytochrome C.     
In addition to its actions as an electron carrier, coenzyme Q10 may act as antioxidant and 
help protect the myocardium from post-ischaemic reperfusion injury. If mitochondrial 
dysfunction is playing a role in migraine genesis then coenzyme Q10 could improve 
mitochondrial function and thus prevent migraine headaches. This belief is not without 
precedence as riboflavin, in an open label study and a placebo-controlled trial has been 
shown to reduce migraine frequency. Riboflavin is indirectly involved in the electron 
transport chain as a precursor of flavin mononucleotides. Coenzyme Q10 is an essential 
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element of the electron transport chain, suggesting that it could also work as migraine 
preventive. 
f) NK-1 receptors: 
According to neurogenic inflammation theory of migraine, SP induces dural 
inflammation and increases sensitization to migraine headache pain by stimulating NK-1 
receptors. Lanepitant is a high affinity, non-peptide, competitive NK-1 receptor antagonist 
that acts both peripherally and centrally and reported to be effective in guinea pig model of 
dural inflammation. Thus, NK-1 receptor antagonists may have a role in migraine therapy. 
g) Nociceptin: 
Nociceptin is an endogenous ligand for the opiate-4 (OP- 4) receptor. The OP-4 
receptor abundantly expressed in various CNS structures in rodents, nonhuman primates     
and in humans, supporting the role of nociceptin in multitude of CNS functions, including 
motor and balance control, reinforcement and reward, nociception, the stress response,    
sexual behavior, aggression and autonomic control of physiologic processes. It has been 
reported that approximately 70% of neurons in the human trigeminal ganglion exhibit 
nociceptin immunoreactivity and express OP-4 receptor mRNA. In these cells nociceptin      
is co-localized with CGRP and substance P, marker peptides of the trigeminovascular    
system. This distribution suggests that nociceptin may be involved in the regulation of 
neuropeptide release from trigeminal nerve terminals and perhaps in migraine.     
Interestingly, in an animal model nociceptin dose-dependently suppressed the neurogenic 
dural vasodilatation, while it had no effect on baseline vessel diameter, also in a recent     
study lower circulating levels of nociceptin was observed during migraine attacks. Hence 
drugs targeting OP-4 receptor might be a promising alternative in the pharmacological 
treatment of migraine. 
h) Melatonin: 
Melatonin is a derivative of essential amino acid tryptophan, synthesized in the    
pineal gland. It has wide therapeutic implications including sleeping disorders, circadian 
rhythm, insomnia in blind people, insomnia in elderly patients, aging and Alzheimer    
disease. It has been observed that some patients reporting their headaches predominantly      
or specifically at a certain period of the day. Both episodic and chronic migrainers reported 
waking up in the morning with headaches or being woken up at night by the headache.      
Also migraine patients without depression had lower levels of melatonin than controls.  
Since, melatonin is involved in cerebrovascular regulation, treatment of headache       
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disorders including migraine is promising. Melatonin may also be involved in migraine 
comorbidity. Insomina in headache patients is the most likely associated condition in 
migraine to respond to melatonin therapy. However, the data from large human trials are     
yet come to provide a proof-of-concept for the potential role of melatonin therapy in 
migraine. 
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    2. LITERATURE SURVEY 
2.1. Literature Review: 
1. Bhalala chirag.,  et al. (2012) formulated bilayer tablets of Metformin HCL and 
Pioglitazone HCL of which Metformin HCL as sustained release and Pioglitazone 
HCL as immediate release layer. Sustained layer were prepared by wet granulation 
method using HPMC K4 as polymer, immediate release layer were prepared by    
direct compression method using superdisintegrants such as crosscarmellose      
sodium. In vitro release studies were carried out by USP type 2 paddle apparatus.    
The result showed that polymer HPMC K4 in sustained layer can control the     
release of drug. The in vitro release profile of drug from sustained release layer     
could be expressed by higuchi’s equation as pilot show high linearity      
R2=0.9911and diffusion was the dominant mechanism of drug release. The 
formulation (F9) having immediate release layer produces immediate effect 
94.53±0.30 within 45 minutes followed by sustained release effect (95.77±0.37)      
upto 8 hours. The present study concluded that Bilayer tablets of Pioglitazone HCL 
and Metformin HCL can be a better alternative to conventional dosage form for 
providing sustained drug delivery. 
2. Chinam Niranjan Patra., et al. (2007) developed a bilayer tablet of propranolol 
hydrochloride using superdisintegrant sodium starch glycolate for the fast release 
layer and water immiscible polymers such as ethylcellulose, Eudragit RLPO and 
Eudragit RSPO for the sustaining layer. In vitro dissolution studies were carried       
out in a USP 24 apparatus I. The formulations gave an initial burst effect to provide 
the loading dose of the drug followed by sustained release for 12 h from the 
sustaining layer of matrix embedded tablets. In vitro dissolution kinetics followed      
the Higuchi model via a non-Fickian diffusion controlled release mechanism after     
the initial burst release. FT-IR studies revealed that there was no interaction      
between the drug and polymers used in the study. Statistical analysis (ANOVA) 
showed no significant difference in the cumulative amount of drug release after 15 
min, but significant difference (p < 0.05) in the amount of drug released after 12 h 
from optimized formulations was observed. 
3. Chitra karthikeyini.S., et al. (2009) developed a bilayer tablet of Aceclofenac 
sodium using superdisintegrant, sodium starch glycolate for the fast release layer     
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and water immiscible polymers such as Eudragit RL100 for the sustaining layer.     
FT-IR studies revealed that there was no interaction between the drug and       
polymers used in the study. In Vitro dissolution studies were carried out in a USP     
type II Paddle type apparatus. The formulation gave an initial burst effect and 
followed by sustained release for 24 hrs. The optimized formulation (F5) showed      
no significant changes on stability studies when storing at 4º c, 40º c, /75%RH, 60º 
c/80% RH for 3 months. The TG /DTA analysis revealed that there was no      
significant interaction between polymers and drug .The drug release from F5 
Formulation was found to zero order kinetics. It was also found linear in Higuchi’s 
plot which confirms that diffusion is one of the mechanism of drug release .In this 
study optimized formulation (F5) release the drug upto 24hrs and fulfilled many 
requirements such as easy to fabricate , cost effective and high patient compliance. 
4. Dhruvita patel., et al. (2012) formulated bilayer tablets containing Metformin HCl  
in extended release matrix form and Pioglitazone HCl in immediate release form      
for the treatment of diabetes mellitus. Influence of hydrophilic carrier, hydrophobic 
polymer on drug release was studied. Immediate release layer of Pioglitazone HCl 
was optimised using different super disintegrants.All formulations are evaluated for 
percentage drug release. Optimisation results indicated that release rate of     
Metformin is directly proportional to the levels of Eudragit S 100 and PEG 6000. 
Results confirmed that bilayer tablet formulation containing extended release of 
Metformin HCl and immediate release of Pioglitazone HCl could be developed by 
using melt granulation technique. 
5. G.Vinoth Kumar., et al. (2011) formulated Bi-layer tablets of Cefixime trihydrate 
and Dicloxacillin sodium using povidone k-30 as binder. Cefixime is a     
cephalosporin antibiotic used to treat infections caused by bacteria such as 
pneumonia, bronchitis, gonorrhea, and ear, lung, throat, and urinary tract        
infections. Dicloxacillin is a semi synthetic antibiotic which resists destruction by    
the enzyme penicillinase. It is used to treat different types of infections caused by 
bacteria such as bronchitis, pneumonia, etc. A total number of nine formulations     
have been taken to optimize and develop a robust and stable formulation. Wet 
granulation process was used for the formulation of both layers.  Among the 
formulations tablets of formulation -5 was taken as optimized formula due to its 
higher rate of dissolution and compiled all the other parameters with the official 
specifications. 
LITERATURE SURVEY                                                                                                      CHAPTER-2 
 
 
ADHIPARASAKTHI COLLEGE OF PHARMACY  34 
 
6. Girish S. Sonar., et al. (2007) developed a bilayer and fl oating-bioadhesive drug 
delivery system exhibiting a unique combination of fl oatation and bioadhesion to 
prolong residence in the stomach using rosiglitazone maleate as a model drug.  The 
sustained layer was compressed and granules of the floating layer were added to it 
then both layers were compressed using a single station rotary press. Granules and 
tablets were characterized using the official method. Hydroxypropyl      
methylcellulose (HPMC) and sodium bicarbonate were added to the floating layer 
and, when immersed in 0.1 mol/l HCl, the tablet expands and rises to the surface 
where the drug is gradually released without interference from gas bubbles.  The in 
vitro drug release from the tablet was controlled by the amount of HPMC in the 
sustained release layer. The fl oating ability of the tablets was studied by gamma 
scintigraphy. The release of rosiglitazone maleate from the tablets followed the 
matrixfi rst-order release model. The concentration of HPMC signifi cantly affects   
the drug release rate, buoyancy lag-time, detachment force and swelling 
characteristics of the tablets. The tablet was buoyant for up to 8 h in the human 
stomach. 
7. Hosna Banu., et al. (2011) designed acetaminophen extended release bi layer      
tablets containing immediate release layer and extended release layer. Tablets were 
prepared by wet granulation technique using different grades of     
hydroxypropylmethyl cellulose (HPMC 15 cps, HPMC 100 cps and Methocel K4m 
CR) as release rate retardant. In vitro release studies were performed using USP     
type II apparatus (paddle method) in 900 mL of 0.1N HCl at 50 rpm for 4 hours      
and compared with USP specification. In vitro release studies revealed that the     
release rate decreased with increase of polymer loading and viscosity. Formulation 
ER-4 (containing 10% HPMC 100 cps and 1.5% sodium starch glycolate) and ER-     
6 (containing 1.5% Methocel K4M CR and 0.5% sodium starch glycolate) were    
found to follow compendia specification for drug release profile. Drug release was 
analyzed using zero-order, first order, Higuchi and Korsmeyer-Peppas equations to 
explore and explain the mechanism of drug release from the bi layer matrix tablets. 
Mathematical analysis of the release kinetics indicated that release from the matrix 
tablets followed Fickian diffusion. So the bi-layer tablets could be a potential     
dosage form for delivering acetaminophen. 
8. Jain Jitendra., et al. (2011) developed a bilayer-floating tablet for Indomethacin 
using direct compression technology. Bilayer tablets were punched using optimized 
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solid dispersion, HPMC K4M, Avicel PH-112, ac-di-sol, magnesium stearate and 
aerosil in fast release layer and optimized floating layer as sustained release layer.    
FT-IR studies revealed that there was no interaction between the drug and       
polymers used in the study. In Vitro dissolution studies were carried out in a USP     
type II Paddle type apparatus. The optimized formulation (A2) showed no      
significant changes on stability     studies when storing at 4º c, 40º c, /75%RH, 60º 
c/80% RH for 3 months. The release data obtained from the dissolution study of the 
bilayer tablets were analysed with respect to first order model, Higuchi model, 
Korsmeyer-Peppas model, and zero order models. In this study optimized     
formulation (A2) release the drug up to 24hrs and fulfilled many requirements. 
9. Kiran muscle., et al. (2011) formulated bilayer tablet of diclofenac sodium and 
pracetamol with diclofenac as sustained release formulation. In the same sustained 
release layer of diclofenac sodium, an immediate layer of paracetamol was      
optimised separately and then constituted in bilayer tablet using the amount of 
polyethylene glycol, microcrystalline cellulose and crospovidone as independent 
variables for fabricating paracetamol tablets. Diclofenac sodium tablets were     
prepared using hydroxylpropylmethylcellulose as a matrixing agent.  
10. MA Naeem., et al. (2010) developed bilayer tablet formulations of tramadol HCl 
(TmH) and acetaminophen (AAP) microparticles using Coacervation via     
temperature change method, with ethyl cellulose (EC) of medium viscosity as the 
polymer for extending drug release. The microparticles of the two drugs were 
prepared separately and then compressed into bilayer tablets. The physicochemical 
compatibility and stability of the tablets were determined by Fourier transform 
infrared spectroscopy (FTIR), x-ray diffractometry (XRD), differential scanning 
calorimetry (DSC) and thermogravimetric analysis (TGA) while their mechanism     
and pattern of drug release were assessed by applying Higuchi, Zero order, First    
order and Korsmeyer-Peppas kinetic models. Bilayer tablets were subjected to 
accelerated stability studies for three months. FTIR, XRD, DSC and TGA data for   
the formulations indicate good compatibility and stability. Furthermore, accelerated 
stability studies confirmed the stability of the formulations. Controlled drug release 
from the microparticles and bilayer tablets was observed for 8 h and 12 h, 
respectively. The Higuchi model produced the best fit, with regard to release      
profile, for both drugs, with correlation coefficient (R2) of 0.966 and 0.960 for      
AAP and TmH, respectively. 
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11. Metkar Vishal., et al. (2012) developed bi-layer tablets of lornoxicam, a highly 
potent nonsteroidal anti-inflammatory drug with short half-life, that are      
characterized by initial burst drug release in the stomach and comply with the     
release requirements of sustained-release products. Each of the proposed bi-layer 
tablets is composed of an immediate-release layer and a sustained-release layer, 
anticipating rapid drug release that starts in the stomach to rapidly alleviate the 
symptoms and continues in the intestine to maintain protracted analgesic effect. 
Immediate release layer prepared by using dry granulation method in which ac-di     
sol used as a disintigrant for immediate release of drug, roll compaction of drug     
with sodium citrate which act as buffering agent and create basic     
microenvironmental pH inside the tablets favorable to drug release in acidic 
conditions. Sustained release layer formulated by using HPMC as release retardant, 
two grades of HPMC that are HPMC K4M and HPMC K100M used to get     
sustained release profile for 24 hr. various trial batches are taken to get desired    
release profile. Batch F8 formulate as bilayer tablet in which drug as to sodium    
citrate ratio taken 1:5 show maximum drug release 24.67 % for 1 hr in immediate 
release layer and drug release 98 % for 24 hr in sustained release layer is selected     
as optimized batch of bilayer tablet formulation. All the prepared bilayer tablets 
showed acceptable physical properties before and after storage. 
12. Modi Foram P., et al. (2011) developed stable cost effective fixed dose     
combination moisture barrier film coated bilayer tablet of two incompatible drug 
artesunate and amodiaquine hydrochloride. Artesunate was very moisture sensitive 
drug so blend of artesunate layer was prepared by dry granulation method and      
blend of amodiaquine hydrochloride layer was prepared by wet granulation      
method. The formula of artesunate layer was optimized using 32 factorial designs      
& using calcium carbonate as basic stabilizing agent. The formula of amodiaquine 
hydrochloride was optimized using PVPK-30 as a binder. Result of this study 
suggested that stable artesunate and amodiaquine hydrochloride moisture barrier     
film coated bilayer tablet could be successfully formulated using calcium carbonate    
as basic stabilizing agent & instamoistshield as moisture barrier coating material. 
13. Mr. Ashish A Pahade.,  et al. (2010) developed bilayer sustained release tablet of 
Isosorbide mononitrate, an anti-anginal organic nitrate vasodilator. The tablets       
were prepared by wet granulation method. Hydrophilic and hydrophobic matrix 
materials such as hydroxypropyl methylcellulose, and polyox were used, which can 
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release the drug up to 24hrs in predetermined rate. Binder used was pvp k-30. The 
influence of hydrophilic and hydrophobic polymer and granulation technique was 
studied.  The invitro release rate profile showed the higher concentration of F6 
polymer in tablet. 
14. Narasaiah., et al. (2010) formulated floating tablet of sumatriptan succinate by wet 
granulation method. The prepared tablets were physically characterised and show 
results within the limit. The in vitro drug release was carried out for 8 hr from that      
it was concluded that the drug release for all the formulations were followed by      
zero order kinetics and peppas modelling. The diffusion exponent was found to be 
non-fickian diffusion mechanism. 
15. Preeti Karwa.,  et al. (2011) designed a bilayer tablet of Zolpidem Tartrate (ZT)      
for biphasic release and in vitro evaluation of the same. Bilayer tablets comprised    
two layers, i.e. immediate release and controlled release layer. The immediate     
release layer comprised croscarmellose sodium as a super disintegrant and the 
controlled release layer comprised HPMC K100M as the release retarding       
polymers. Direct compression method was used for formulation of the bilayer     
tablets. In vitro dissolution studies were carried out in a USP apparatus I, basket 
method. HPMC K100M extended the release of drug from the extended release     
layer for 6 hr. FTIR studies revealed that there was no interaction between the drug 
and polymers used in the study. The release of Zolpidem Tartrate was found to    
follow a pattern of Korsmeyer-Peppas, with Quasi-Fickian diffusion. Accelerated 
stability studies were carried out on the prepared tablets in accordance with ICH 
guidelines. There were no changes observed in physicochemical properties and      
drug release pattern of tablets. Biphasic drug release pattern was successfully 
achieved through the formulation of bilayer tablets in this study. 
16.  R.Natarajan., et al. (2011) formulated  Antihypertensive drugs of the Telmisartan 
and Hydrochlorothiazide immediate release Bilayer tablet, and to study the 
dissolution profile with the reference product. The Formulation development work 
was initiated with Wet granulation. Telmisartan is converted to its sodium salt by 
dissolving in aqueous solution of Sodium Hydroxide, in order to improve solubility 
and drug release. Lactose Monohydrate and Microcrystalline Cellulose are used as 
diluents. Starch paste is prepared in Purified Water and is used as the binder.     
Sodium Starch Glycolate is added as a disintegrating agent. Magnesium Stearate is 
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used as the lubricant. The prepared granules are compressed into Double layer 
compression machine. The tablets thus formulated with higher proportion of      
sodium starch glycolate showed satisfactory physical parameters, and it was found     
to be stable and in-vitro release studies are shown that formulation (F-T5H5) was 
101.11% and 99.89% respectively. And the formulation T5H5 is further selected     
and compared with the release profile of innovator product, it was found to be     
similar (f2 factor) to that of marketed product. 
17. R.T. Jadhav., et al. (2011) formulated Bi-layer tablets of Piracetam and     
Vinpocetine, so that synergistic effect of this combination could be used for the 
effective treatment of Alzheimer Disease. Wet granulation process was used for the 
formulation of both layers and the final film coated tablets were evaluated for the 
thickness, weight variation, hardness, friability, disintegration time, dissolution     
study. Among the formulation, tablets of batch V2 of vinpocetine & batch P3 of 
piracetam was taken as optimized formula due to its higher rate of dissolution and 
complied all the other parameters with the official specifications. The stability      
study of the selected formulations was done at 40°C and 75% RH for 3 months. It   
was concluded that Piracetam, Vinpocetine Bi-layer tablets can be prepared 
successfully as it satisfies all the criteria as a Bilayered tablet and would be     
alternative to the currently available conventional tablets. 
18. Remya P.N., et al. (2010) developed a robust formulation of  bilayered tablets of  
Ibuprofen and methocarbamol using povidone k-30 as binder.  The mechanism of 
methocarbamol is a skeletal muscle relaxant which acting centrally through     
inhibiting inter neuronal activity and blocking polysynaptic reflex pathway at       
spinal card. Ibuprofen is a pain relieving agent which inhibits the activity of 
Cyclooxygenase an enzyme crucial for synthesis of prostaglandins. A total number    
of nine formulations have been taken to optimize and develop a robust and stable 
formulation. Wet granulation process was used for the formulation of both layers. 
Among the formulations tablets of formulation -8 was taken as optimized formula     
due to its higher rate of dissolution and compiled all the other parameters with          
the official specifications. 
19. S. Jayaprakash., et al. (2011) formulated bilayer tablets of Amlodipine besilate     
(IR) Metoprolol succinate (SR) for the management of hypertension. In the 
formulation of immediate release sodium starch glycolate and pregelatinised starch 
were used as super disintegrant and was directly compressed. For sustained release 
LITERATURE SURVEY                                                                                                      CHAPTER-2 
 
 
ADHIPARASAKTHI COLLEGE OF PHARMACY  39 
 
portion HPMC polymers were used in granulation stage and also extragranularly. 
Preformulation studies were performed prior to compression. The compressed    
bilayer tablets were evaluated for weight variation, dimension, hardness, friability, 
drug content, disintegration time and invitro drug release using USP dissolution 
apparatus type 2 (paddle). It was found that the optimized formulation showed    
9.96%, 35.56%, 52.12%, 90.46% release for Metoprolol succinate in 1, 4, 8, 20     
hours respectively. However, Amlodipine besilate released 98.28% at the end of 30 
minutes. The IR spectrum and DSC studies revealed that there is no disturbance in   
the principal peaks of pure drugs Metoprolol succinate and Amlodipine besilate.     
This further confirms the integrity of pure drugs and no incompatibility of them    
with excipients. The stability studies were carried out for the optimized batch for    
three months and it showed acceptable results. The kinetic studies of the     
formulations revealed that diffusion is the predominant mechanism of drug and 
release follows first order kinetics. 
20. Sharmin Rahman., et al. (2012) formulated bilayer tablets of tramadol    
hydrochloride by direct compression technique incorporating an immediate release 
layer and a sustained release layer. An immediate release layer was successfully 
designed to release the bolus dose instantaneously. Water soluble Xanthan gum,    
water insoluble Kollidon SR and Eudragit L 100 were used as carriers in the    
sustained release layer of the matrix tablet. The in vitro drug release was studied      
for eight hour, first two hours dissolution in acidic medium followed by six hour 
dissolution in buffer medium. Matrix tablet showed a sustained release rate with a 
controlled fashion as a function of the quantity of polymer used. The in vitro drug 
release data were fitted with several mathematical models and mean dissolution     
time along with fractional dissolution time values (T25%, T50% and T80%) were 
calculated. Xanthan gum was found to be the most effective rate retarding agent 
compared to Kollidon SR and Eudragit L 100, when used at same ratio in the 
formulations. 
21. Supriya S. Shidhaye., et al. (2008) developed and optimized formulations of 
mucoadhesive bilayered buccal patches of sumatriptan succinate using chitosan as    
the base matrix and was prepared by the solvent casting method. Gelatin and 
polyvinyl pyrrolidone (PVP) K30 were incorporated into the patches, to improve     
the film properties of the patches. The prepared patches were evaluated for      
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different parameters and it was concluded that the permeation can be increased 
through the buccal mucosa by using different penetration enhancers. 
22. Yelanki., et al. (2010) developed the sumatriptan nasal mucoadhesive minitablets 
using different mucoadhesive polymes like chitosan, carbopol 971p, gum copal and 
HPMC K4M with different ratios and evaluated for thickness, hardness, swelling 
index, mucoadhesion strength and in vitro drug release. It was observed that the 
tablets shows controlled release of drug upto 7days and the release data was fit into 
different kinetic models. 
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2.2 DRUG PROFILE  
(SweetmanSC(Eds), Matrindale.,2002; Neil IM(Eds).,2001; Goodman and Gilman) 
 
SUMATRIPTAN SUCCINATE: 
Sumatriptan succinate is 3-[2-(dimethyl amino) ethyl]-N-methyl-1H-indole-5-methane 
sulfonamide succinate. It is 5-HT1receptor agonist used in the treatment of migraine. 
 
Structure : 
 
     
 
IUPAC Name  : [3-[2-(Dimethylamino)ethyl]-1H-indole-5-yl]-N-              
methylmethanesulphonamide hydrogen butanedioate. 
Formula : C18H27N3O6S 
Molecular mass : 413.5 
Drug category : Anti-migraine agents, Selective Serotonin agonists, Serotonin 
agonists, Vasoconstrictor agents. 
Indication : For the treatment of migraine attacks with or without aura 
Bioavailability : 15% (oral) and 96% (s.c) 
Half life : 2.5 hours 
Protein binding   : 14%-21% 
Melting point    : 166-171 oC 
Description    : White or almost white powder. 
Solubility : Freely soluble in water, sparingly soluble in methanol,   practically 
insoluble in methylene chloride. 
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PHARMACOLOGY: 
Mechanism of action: The 5-HT1B and 5-HT1D receptors function as autoreceptors, which 
inhibit the firing of serotonin neurons and a reduction in the synthesis and release of 
serotonin upon activation. After sumatriptan binds to these receptors, adenylate cyclase 
activity is inhibited via regulatory G proteins, increases intracellular calcium, and affects 
other intracellular events. This results in vasoconstriction and inhibtion of sensory 
nociceptive (trigeminal) nerve firing and vasoactive neuropeptide release. 
Pharmacokinetics: 
Absorption: Sumatriptan is rapidly but incompletely absorbed when given orally and 
undergoes first pass metabolism, resulting in a low absolute bioavailability. 
Metabolism: It is extensively metabolised in the liver predominantly by monoamine     
oxidase type A. Sumatriptan and its metabolite also appear in the faces, small amounts of 
sumatriptan are distributed in breast milk. 
Excretion: Sumatriptan is excreted mainly in the urine as the inactive indole acetic    
derivative and its glucuronide. 
Pharmacodynamics: Sumatriptan, an antimigraine drug, is a selective agonist of vascular 
serotonin ((5-hydroxytryptamine; 5-HT) type 1-like receptors, likely the 5-HT1D and 5-
HT1B subtypes. It has no significant affinity (as measured using standard radioligand     
binding assays) or pharmacological activity at 5-HT2, 5-HT3 receptor subtypes or at     
alpha1-, alpha2- or beta-adrenergic; dopamine1; dopamine2; muscarinic; or       
benzodiazepine receptors. 
Toxicity: Symptoms of overdose include convulsions, tremor, paralysis, inactivity, ptosis, 
erythema of the extremities, abnormal respiration, cyanosis, ataxia, mydriasis, salivation,    
and lacrimation. 
Indications: For the treatment of migraine attacks with or without aura in adults. 
Sumatriptan is an antimigraine drug structurally similar to serotonin. It is thought that the 
cerebral blood vessel constriction induced by activation of 5HT1 receptors on those vessels 
may contribute to the antimigranious effect of sumatriptan in humans. 
Side effects: Rare cardiac events have been associated with the administration of 5-HT1 
agonists including coronary artery vasopasm, atrial and ventricular arrhythmias and 
myocardial infarction. Large doses of sumatriptan can cause sulphahemoglobinemia a rare 
condition in which the blood changes from red to greenish black due to the integration of 
sulphur into the haemoglobin molecule. 
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Contraindications: 
 Patients with a known hypersensitivity to sumatriptan or any of the tablet 
excipients. 
 Patients who have had myocardial infarction or have ischaemic heart disease, 
coronary vasospasm (Prinzmetal’s angina), peripheral vascular disease or patients 
who have symptoms or sign consistent with ischaemic heart disease. 
 Patients with a history of cerebrovascular accident (CVA) or transient ischaemic 
attack (TIA). 
 Patients with severe hepatic impairment. 
 Patients with moderate and severe hypertension and mild uncontrolled 
hypertension. 
 Concomitant administration of ergotamine or derivatives of ergotamine      
(including methysergide) is contraindicated.  
 Concurrent administration of monoamine oxidase inhibitors and sumatriptan is 
contraindicated. 
 Sumatriptan tablets must not be used within two weeks of discontinuation of 
therapy with monoamine oxidase inhibitors. 
Special warnings and precautions for use: 
 Sumatriptan tablets should only be used where there is a clear diagnosis of 
migraine. 
 Sumatriptan is not indicated for use in the management of hemiplegic, basilar or 
ophthalmoplegic migraine. 
 The recommended doses should not be exceeded. As with other migraine    
therapies, before treating headaches in patients not previously diagnosed as 
migraineurs, and in migraineurs who present atypical symptoms, care should be 
taken to exclude other potentially serious neurological conditions. 
 It should be noted that migraineurs may be at risk of certain cerebrovascular    
events (e.g. cerebrovascular accident, transient ischaemic attack). 
 Following administration, sumatriptan can be associated with transient symptoms 
including chest pain and tightness which may be intense and involve the throat.     
Where such symptoms are thought to indicate ischaemic heart                           
disease, no further doses of sumatriptan tablets should be given and appropriate 
evaluation should be carried out. 
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 Sumatriptan tablets should not be given to patients with risk factors for ischaemic 
heart disease without prior cardiovascular evaluation. Special                  
consideration should be given to postmenopausal women and males over 40 with 
these risk factors. These evaluations however, may not identify every patient who 
has cardiac disease and, in very rare cases, serious cardiac events have occurred      
in patients without underlying cardiovascular disease. 
 Sumatriptan tablets should be administered with caution to patients with      
controlled hypertension as transient increases in blood pressure and peripheral 
vascular resistance have been observed in a small proportion of patients. 
 There have been rare post-marketing reports describing patients with weakness, 
hyper-reflexia, and incoordination following the use of a selective serotonin 
reuptake inhibitor (SSRI) and sumatriptan. If concomitant treatment with 
sumatriptan and an SSRI is clinically warranted, appropriate observation of the 
patient is advised. 
 Sumatriptan tablets should be administered with caution to patients with     
conditions which may affect significantly the absorption, metabolism or      
excretion of drugs, e.g. impaired hepatic or renal function. 
 Sumatriptan should be used with caution in patients with a history of seizures or 
other risk factors which lower the seizure threshold, as seizures have been     
reported in association with sumatriptan (see section 4.8) 
 Patients with known hypersensitivity to sulphonamides may exhibit an allergic 
reaction following administration of sumatriptan tablets. Reactions may range    
from cutaneous hypersensitivity to anaphylaxis. Evidence of cross-sensitivity is 
limited but caution should be exercised before using sumatriptan in these       
patients. 
 Undesirable effects may be more common during concomitant use of triptans and 
herbal preparations containing St Johns wort (Hypericum perforatum). These   
tablets contain lactose. Patients with rare hereditary problems of galactose 
intolerance, the lactase deficiency or glucose-galactose malabsorption should not 
take this medicine. 
 As with other acute migraine treatments, chronic daily headache/exacerbation of 
headache have been reported with overuse of sumatriptan, which may necessitate     
a medicinal product withdrawal. 
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Interaction with other medicinal products and other forms of interaction: 
 Studies in healthy subjects show that sumatriptan does not interact with      
propranolol, flunarizine, pizotifen or alcohol. Sumatriptan has the potential to     
interact with MAOIs, ergotamine and derivatives of ergotamine. The increased risk    
of coronary vasospasm is a theoretical possibility and concomitant administration is 
contraindicated. 
 Prolonged vasospastic reactions have been reported with ergotamine. As these      
effects may be additive, 24 hours should elapse before sumatriptan tablets can be 
taken following any ergotamine-containing preparation. Conversely, ergotamine-
containing preparations should not be taken until 6 hours have elapsed following 
administration. 
 Rarely, an interaction may occur between sumatriptan and SSRIs. 
 There may be a risk of serotonergic syndrome also if sumatriptan is used 
concomitantly with lithium. 
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2.3 EXCIPIENT PROFILE 
(Raymond CR) 
2.3.1 GUAR GUM: 
1. Nonproprietary Names: 
• BP: Guar galactomannan 
• PhEur: Guar galactomannanum 
• USPNF: Guar gum 
2. Synonyms: 
E412; Galactosol; guar flour; jaguar gum; Meyprogat; Meyprodor; Meyprofin. 
3. Chemical Name and CAS Registry Number: 
Galactomannan polysaccharide [9000-30-0] 
4. Empirical Formula and Molecular Weight: 
(C6H12O6) n =220 000 
5. Structural Formula: 
Guar gum consists of linear chains of (1→4)-β-D-mannopyranosyl units with α-D-
galactopyranosyl units attached by (1→6) linkages. The ratio of D-galactose to D-mannose     
is between 1:1.4 and 1:2.. 
6. Functional Category: 
Suspending agent, tablet binder, tablet disintegrant and viscosity increasing agent. 
7. Applications in Pharmaceutical Formulation or Technology: 
Guar gum is a galactomannan, commonly used in cosmetics, food products, and 
pharmaceutical formulations. It has also been investigated in the preparation of sustained-
release matrix tablets in the place of cellulose derivatives such as methylcellulose. 
In pharmaceuticals, guar gum is used in solid-dosage forms as a binder and disintegrant, in 
oral and topical products as a suspending, thickening, and stabilizing agent; and also as a 
controlled-release carrier. Guar gum has also been examined for use in colonic drug     
delivery. Guar-gum-based three-layer matrix tablets have been used experimentally in oral      
controlled-release formulations. 
8. Description: 
The USPNF 23 describes guar gum as a gum obtained from the ground endosperms    
of Cyamopsis tetragonolobus (L.) Taub. (Fam. Leguminosae). It consists chiefly of a high-
molecular-weight hydrocolloidal polysaccharide, composed of galactan and mannan units 
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combined through glycoside linkages, which may be described chemically as a 
galactomannan. The PhEur 2005 similarly describes guar galactomannan as being obtained 
from the seeds of Cyamopsis tetragonolobus (L.) Taub. by grinding the endosperms and 
subsequent partial hydrolysis. 
The main components are polysaccharides composed of D-galactose and D-mannose in 
molecular ratios of 1:1.4 to 1:2. The molecule consists of a linear chain of β-(1→4)-
glycosidically linked manno-pyranoses and single α-(1→6)-glycosidically linked galacto-
pyranoses. Guar gum occurs as an odorless or nearly odorless, white to yellowish-white 
powder with a bland taste. 
9.  Typical Properties: 
Acidity/alkalinity:  pH = 5.0–7.0 (1% w/v aqueous dispersion) 
Density: 1.492 g/cm3 
Solubility: Practically insoluble in organic solvents. In cold or hot water, guar gum 
disperses and swells almost immediately to form a highly viscous, thixotropic sol.   
The optimum rate of hydration occurs at pH 7.5–9.0. Finely milled powders swell 
more rapidly and are more difficult to disperse. Two to four hours in water at room 
temperature are required to develop maximum viscosity. 
Viscosity (dynamic): 4.86 Pa s (4860 cP) for a 1% w/v dispersion. Viscosity is 
dependent upon temperature, time, concentration, pH, rate of agitation, and particle 
size of the guar gum powder. 
 10. Stability and Storage Conditions: 
Aqueous guar gum dispersions have a buffering action and are stable at pH 4.0–   
10.5. However, prolonged heating reduces the viscosity of dispersions. 
The bacteriological stability of guar gum dispersions may be improved by the addition of a 
mixture of 0.15% methylparaben and 0.02% propylparaben as a preservative. In food 
applications, benzoic acid, citric acid, sodium benzoate, or sorbic acid may be used. 
Guar gum powder should be stored in a well-closed container in a cool, dry place. 
11. Incompatibilities: 
Guar gum is compatible with most other plant hydrocolloids such as tragacanth. It      
is incompatible with acetone, ethanol (95%), tannins, strong acids, and alkalis. Borate ions,   
if present in the dispersing water, will prevent the hydration of guar gum. However, the 
addition of borate ions to hydrated guar gum produces cohesive structural gels and further 
hydration is then prevented. The gel formed can be liquefied by reducing the pH to below    
7, or by heating. 
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2.3.2   XANTHAN GUM: 
1. Nonproprietary Names: 
• BP: Xanthan gum 
• PhEur: Xanthani gummi 
• USPNF: Xanthan gum 
2. Synonyms: 
Corn sugar gum; E415; Keltrol; polysaccharide B-1459; Rhodigel; Vanzan NF; 
Xantural. 
3. Chemical Name and CAS Registry Number: 
Xanthan gum [11138-66-2] 
4. Empirical Formula and Molecular Weight: 
(C35H49O29)n Approximately 2 × 106 
The USPNF 23 describes xanthan gum as a high molecular weight polysaccharide 
gum. It contains D-glucose and D-mannose as the dominant hexose units, along with D-
glucuronic acid, and is prepared as the sodium, potassium, or calcium salt. 
5. Structural Formula: 
Each xanthan gum repeat unit contains five sugar residues: two glucose, two 
mannose, and one glucuronic acid. The polymer backbone consists of four β-D-glucose     
units linked at the 1 and 4 positions, and is therefore identical in structure to cellulose. 
Trisaccharide side chains on alternating hydroglucose units distinguish xanthan from 
cellulose. Each side chain comprises a glucuronic acid residue between two mannose units. 
At most of the terminal mannose units is a pyruvate moiety; the mannose nearest the main 
chain carries a single group at C-6. The resulting stiff polymer chain may exist in solution     
as a single, double, or triple helix that interacts with other xanthan gum molecules to form 
complex, loosely bound networks. 
6. Functional Category: 
Stabilizing agent; suspending agent; viscosity-increasing agent. 
7. Applications in Pharmaceutical Formulation or Technology: 
Xanthan gum is widely used in oral and topical pharmaceutical formulations, 
cosmetics, and foods as a suspending and stabilizing agent. It is also used as a thickening     
and emulsifying agent. It is nontoxic, compatible with most other pharmaceutical    
ingredients, and has good stability and viscosity properties over a wide pH and temperature        
range. Xanthan gum gels show pseudoplastic behavior, the shear thinning being directly 
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proportional to the shear rate. The viscosity returns to normal immediately on release of   
shear stress. 
When xanthan gum is mixed with certain inorganic suspending agents, such as 
magnesium aluminum silicate, or organic gums, synergistic rheological effects occur. In 
general, mixtures of xanthan gum and magnesium aluminum silicate in ratios between 1:2 
and 1:9 produce the optimum properties. Similarly, optimum synergistic effects are      
obtained with xanthan gum: guar gum ratios between 3:7 and 1:9. 
Although primarily used as a suspending agent, xanthan gum has also been used to prepare 
sustained-release matrix tablets. Controlled-release tablets of diltiazem hydrochloride 
prepared using xanthan gum have been reported to sustain the drug release in a predictable 
manner and the drug release profiles of these tablets were not affected by pH and agitation 
rate. 
Xanthan gum has been incorporated in an ophthalmic liquid dosage form, which 
interacts with mucin, thereby helping in the prolonged retention of the dosage form in the 
precorneal area. 
Recent studies have revealed that xanthan gum can also be used as an excipient for 
spray-drying and freeze-drying processes for better results. 
Xanthan gum can be used to increase the bioadhesive strength in vaginal     
formulations and as a binder in colon specific drug delivery systems. 
Xanthan gum is also used as a hydrocolloid in the food industry, and in cosmetics it 
has been used as a thickening agent in shampoo. 
8. Description: 
Xanthan gum occurs as a cream- or white-colored, odorless, free-flowing, fine 
powder. 
9. Typical Properties: 
Acidity/alkalinity: pH = 6.0–8.0 for a 1% w/v aqueous solution. 
Freezing point: 0°C for a 1% w/v aqueous solution. 
Heat of combustion:  14.6 J/g (3.5 cal/g) 
Melting point: chars at 270°C. 
Particle size distribution: various grades with different particle sizes are available; 
for example, 100% less than 180 µm in size for Keltrol CG; 100% less than 75 µm in 
size for Keltrol CGF; 100% less than 250 µm, 95% less than 177 µm in size for 
Rhodigel; 100% less than 177 µm, 92% less than 74 µm in size for Rhodigel 200. 
Refractive index: n20D = 1.333 for a 1% w/v aqueous solution. 
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Solubility: practically insoluble in ethanol and ether; soluble in cold or warm      
water. 
Specific gravity: 1.600 at 25°C 
Viscosity (dynamic): 1200–1600 mPa s (1200–1600 cP) for a 1% w/v aqueous 
solution at 25°C. 
10. Stability and Storage Conditions: 
Xanthan gum is a stable material. Aqueous solutions are stable over a wide pH    
range (pH 3–12), although they demonstrate maximum stability at pH 4–10 and     
temperatures of 10–60°C. Xanthan gum solutions of less than 1% w/v concentration may      
be adversely affected by higher than ambient temperatures: for example, viscosity is    
reduced. Solutions are also stable in the presence of enzymes, salts, acids, and bases. 
The bulk material should be stored in a well-closed container in a cool, dry place. 
11. Incompatibilities: 
Xanthan gum is an anionic material and is not usually compatible with cationic 
surfactants, polymers, or preservatives as precipitation occurs. Anionic and amphoteric 
surfactants at concentrations above 15% w/v cause precipitation of xanthan gum from a 
solution. 
Under highly alkaline conditions, polyvalent metal ions such as calcium cause 
gelation or precipitation; this may be inhibited by the addition of a glucoheptonate 
sequestrant. The presence of low levels of borates (<300 ppm) can also cause gelation. This 
may be avoided by increasing the boron ion concentration or by lowering the pH of a 
formulation to less than pH 5. The addition of ethylene glycol, sorbitol, or mannitol may     
also prevent this gelation. 
Xanthan gum is compatible with most synthetic and natural viscosity-increasing 
agents. If it is to be combined with cellulose derivatives, then xanthan gum free of cellulase 
should be used to prevent depolymerization of the cellulose derivative. 
The viscosity of xanthan gum solutions is considerably increased, or gelation occurs, in the 
presence of some materials such as ceratonia, guar gum, and magnesium aluminum silicate. 
This effect is most pronounced in deionized water and is reduced by the presence of salt.     
This interaction may be desirable in some instances and can be exploited to reduce the 
amount of xanthan gum used in a formulation; Xanthan gum solutions are stable in the 
presence of up to 60% water-miscible organic solvents such as acetone, methanol, ethanol,    
or propan-2-ol. However, above this concentration precipitation or gelation occurs. 
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Xanthan gum is incompatible with oxidizing agents, some tablet film-coatings, 
carboxymethylcellulose sodium, dried aluminum hydroxide gel, and some active       
ingredients such as amitriptyline, tamoxifen, and verapamil. 
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2.3.3 SODIUM ALGINATE: 
1. Nonproprietary Names: 
• BP: Sodium alginate 
• PhEur: Natrii alginas 
• USPNF: Sodium alginate 
2. Synonyms: 
Algin; alginic acid, sodium salt; E401; Kelcosol; Keltone; Protanal; sodium 
polymannuronate. 
3. Chemical Name and CAS Registry Number: 
Sodium alginate [9005-38-3] 
4. Empirical Formula and Molecular Weight: 
Sodium alginate consists chiefly of the sodium salt of alginic acid, which is a     
mixture of polyuronic acids composed of residues of D-mannuronic acid and L-guluronic 
acid. 
The block structure and molecular weight of sodium alginate samples has been 
investigated. 
5. Functional Category: 
Stabilizing agent; suspending agent; tablet and capsule disintegrant; tablet binder; 
viscosity-increasing agent. 
6. Applications in Pharmaceutical Formulation or Technology: 
Sodium alginate is used in a variety of oral and topical pharmaceutical       
formulations. In tablet formulations, sodium alginate may be used as both a binder and 
disintegrant; it has been used as a diluent in capsule formulations. Sodium alginate has also 
been used in the preparation of sustained-release oral formulations since it can delay the 
dissolution of a drug from tablets, capsules, and aqueous suspensions. 
In topical formulations, sodium alginate is widely used as a thickening and suspending      
agent in a variety of pastes, creams, and gels, and as a stabilizing agent for oil-in-water 
emulsions. 
Recently, sodium alginate has been used for the aqueous microencapsulation of    
drugs, in contrast with the more conventional microencapsulation techniques which use 
organic-solvent systems. It has also been used in the formation of nanoparticles. 
The adhesiveness of hydrogels prepared from sodium alginate has been investigated and     
drug release from oral mucosal adhesive tablets, and buccal gels, based on sodium alginate 
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has been reported. Other novel delivery systems containing sodium alginate include 
ophthalmic solutions that form a gel in situ when administered to the eye; an in situ       
forming gel containing paracetamol for oral administration; and a freeze-dried device 
intended for the delivery of bone-growth factors. 
Hydrogel systems containing alginates have also been investigated for delivery of 
proteins and peptides. 
Therapeutically, sodium alginate has been used in combination with an H2-receptor 
antagonist in the management of gastroesophageal reflux, and as a hemostatic agent in 
surgical dressings. Alginate dressings, used to treat exuding wounds, often contain      
significant amounts of sodium alginate as this improves the gelling properties. Sponges 
composed of sodium alginate and chitosan produce a sustained drug release and may be 
useful as wound dressings or as tissue engineering matrices 
Sodium alginate is also used in cosmetics and food products. 
7. Description: 
Sodium alginate occurs as an odorless and tasteless, white to pale yellowish-brown 
colored powder. 
8. Typical Properties: 
Acidity/alkalinity: pH ≈7.2 for a 1% w/v aqueous solution. 
Solubility: practically insoluble in ethanol (95%), ether, chloroform, and 
ethanol/water mixtures in which the ethanol content is greater than 30%. Also, 
practically insoluble in other organic solvents and aqueous acidic solutions in which 
the pH is less than 3. Slowly soluble in water, forming a viscous colloidal solution. 
Viscosity (dynamic): various grades of sodium alginate are commercially available 
that yield aqueous solutions of varying viscosity. Typically, a 1% w/v aqueous 
solution, at 20°C, will have a viscosity of 20–400 mPa s (20–400 cP). Viscosity may 
vary depending upon concentration, pH, temperature, or the presence of metal       
ions. Above pH 10, viscosity decreases. 
9. Stability and Storage Conditions: 
Sodium alginate is a hygroscopic material, although it is stable if stored at low 
relative humidities and a cool temperature. 
Aqueous solutions of sodium alginate are most stable at pH 4–10. Below pH 3,    
alginic acid is precipitated. A 1% w/v aqueous solution of sodium alginate exposed to 
differing temperatures had a viscosity 60–80% of its original value after storage for 2 years. 
Solutions should not be stored in metal containers. 
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Sodium alginate solutions are susceptible on storage to microbial spoilage, which    
may affect solution viscosity. Solutions are ideally sterilized using ethylene oxide, although 
filtration using a 0.45 µm filter also has only a slight adverse effect on solution viscosity. 
Heating sodium alginate solutions to temperatures above 70°C causes depolymerization    
with a subsequent loss of viscosity. Autoclaving of solutions can cause a decrease in 
viscosity, which may vary depending upon the nature of any other substances present. 
Gamma irradiation should not be used to sterilize sodium alginate solutions since this     
process severely reduces solution viscosity. 
Preparations for external use may be preserved by the addition of 0.1%     
chlorocresol, 0.1% chloroxylenol, or parabens. If the medium is acidic, benzoic acid may    
also be used. 
The bulk material should be stored in an airtight container in a cool, dry place. 
10. Incompatibilities: 
Sodium alginate is incompatible with acridine derivatives, crystal violet, 
phenylmercuric acetate and nitrate, calcium salts, heavy metals, and ethanol in     
concentrations greater than 5%. Low concentrations of electrolytes cause an increase in 
viscosity but high electrolyte concentrations cause salting-out of sodium alginate; salting-   
out occurs if more than 4% of sodium chloride is present. 
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2.3.4 CROSPOVIDONE: 
1. Nonproprietary Names: 
• BP: Crospovidone 
• PhEur: Crospovidonum 
• USPNF: Crospovidone 
2. Synonyms: 
Crosslinked povidone; E1202; Kollidon CL; Kollidon CL-M; Polyplasdone XL; 
Polyplasdone XL-10; polyvinylpolypyrrolidone; PVPP; 1-vinyl-2-pyrrolidinone 
homopolymer. 
3. Chemical Name and CAS Registry Number: 
1-Ethenyl-2-pyrrolidinone homopolymer [9003-39-8] 
4. Empirical Formula and Molecular Weight: 
(C6H9NO)n >1 000 000 
The USPNF 23 describes crospovidone as a water-insoluble synthetic crosslinked 
homopolymer of N-vinyl-2-pyrrolidinone. An exact determination of the molecular weight 
has not been established because of the insolubility of the material. 
5. Functional Category: 
Tablet disintegrant. 
6. Applications in Pharmaceutical Formulation or Technology: 
Crospovidone is a water-insoluble tablet disintegrant and dissolution agent used at    
2–5% concentration in tablets prepared by direct-compression or wet- and dry-granulation 
methods. It rapidly exhibits high capillary activity and pronounced hydration capacity, with 
little tendency to form gels. Studies suggest that the particle size of crospovidone strongly 
influences disintegration of analgesic tablets. Larger particles provide a faster       
disintegration than smaller particles. Crospovidone can also be used as a solubility       
enhancer. With the technique of co-evaporation, crospovidone can be used to enhance the 
solubility of poorly soluble drugs. The drug is adsorbed on to crospovidone in the presence of 
a suitable solvent and the solvent is then evaporated. This technique results in faster 
dissolution rate. 
7. Description: 
Crospovidone is a white to creamy-white, finely divided, free-flowing, practically 
tasteless, odorless or nearly odorless, hygroscopic powder. 
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8. Stability and Storage Conditions: 
Since crospovidone is hygroscopic, it should be stored in an airtight container in a 
cool, dry place. 
9. Incompatibilities: 
Crospovidone is compatible with most organic and inorganic pharmaceutical 
ingredients. When exposed to a high water level, crospovidone may form molecular      
adducts with some materials.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LITERATURE SURVEY                                                                                                      CHAPTER-2 
 
 
ADHIPARASAKTHI COLLEGE OF PHARMACY  57 
 
2.3.5 STARCH: 
1. Nonproprietary Names: 
• BP:   Maize starch 
• Potato starch 
• Rice starch 
• Tapioca starch 
• Wheat starch 
• JP:    Corn starch 
• Potato starch 
• Rice starch 
• Wheat starch 
• PhEur:    Maydis amylum (maize starch) 
• Solani amylum (potato starch) 
• Oryzae amylum (rice starch) 
• Tritici amylum (wheat starch) 
• USPNF:    Corn starch 
• Potato starch 
• Tapioca 
• Wheat starch 
2. Synonyms: 
Amido; amidon; amilo; amylum; Aytex P; C*PharmGel; Fluftex W; Instant Pure-Cote; 
Melojel; Meritena; Paygel 55; Perfectamyl D6PH; Pure-Bind; Pure-Cote; Pure-Dent;       
Pure-Gel; Pure-Set; Purity 21; Purity 826; Tablet White. 
3. Chemical Name and CAS Registry Number: 
Starch [9005-25-8] 
4. Empirical Formula and Molecular Weight: 
(C6H10O5)n 50 000–160 000 
Where n = 300–1000. 
Starch consists of amylose and amylopectin, two polysaccharides based on α-    
glucose. 
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5. Structural Formula: 
 
6. Functional Category: 
Glidant; tablet and capsule diluent; tablet and capsule disintegrant; tablet binder.
 
7. Applications in Pharmaceutical Formulation or Technology:
Starch is used as an excipient primarily in oral solid
utilized as a binder, diluent, and disintegrant.
As a diluent, starch is used for the preparation of standardized triturates of colorants or 
potent drugs to facilitate subsequent mixing or blending processes in manufacturing 
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operations. Starch is also used in dry-filled capsule formulations for volume adjustment of    
the fill matrix. 
In tablet formulations, freshly prepared starch paste is used at a concentration of 5–
25% w/w in tablet granulations as a binder. Selection of the quantity required in a given 
system is determined by optimization studies, using parameters such as granule friability, 
tablet friability, hardness, disintegration rate, and drug dissolution rate. 
Starch is one of the most commonly used tablet disintegrants at concentrations of     
3–15% w/w. However, unmodified starch does not compress well and tends to increase     
tablet friability and capping if used in high concentrations. In granulated formulations,      
about half the total starch content is included in the granulation mixture and the balance as 
part of the final blend with the dried granulation. Also, when used as a disintegrant, starch 
exhibits type II isotherms and have a high specific surface for water sorption. 
Starch has been investigated as an excipient in novel drug delivery systems for     
nasal, oral, periodontal, and other site-specific delivery systems. 
Starch is also used in topical preparations; for example, it is widely used in dusting 
powders for its absorbency, and is used as a protective covering in ointment formulations 
applied to the skin. Starch mucilage has also been applied to the skin as an emollient, has 
formed the base of some enemas, and has been used in the treatment of iodine poisoning. 
Therapeutically, rice starch-based solutions have been used in the prevention and 
treatment of dehydration due to acute diarrheal diseases. 
8. Description: 
Starch occurs as an odorless and tasteless, fine, white-colored powder comprising    
very small spherical or ovoid granules whose size and shape are characteristic for each 
botanical variety. 
9. Stability and Storage Conditions: 
Dry, unheated starch is stable if protected from high humidity. When used as a    
diluent or disintegrant in solid-dosage forms, starch is considered to be inert under normal 
storage conditions. However, heated starch solutions or pastes are physically unstable and     
are readily attacked by microorganisms to form a wide variety of starch derivatives and 
modified starches that have unique physical properties. Starch should be stored in an     
airtight container in a cool, dry place. 
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2.3.6 MAGNESIUM STEARATE: 
1. Nonproprietary Names: 
• BP: Magnesium stearate 
• JP: Magnesium stearate 
• PhEur: Magnesii stearas 
• USPNF: Magnesium stearate 
2. Synonyms: 
Magnesium octadecanoate; octadecanoic acid, magnesium salt; stearic acid, 
magnesium salt. 
3. Chemical Name and CAS Registry Number: 
Octadecanoic acid magnesium salt [557-04-0] 
4. Empirical Formula and Molecular Weight: 
C36H70MgO4 591.34 
The USPNF 23 describes magnesium stearate as a compound of magnesium with a 
mixture of solid organic acids that consists chiefly of variable proportions of magnesium 
stearate and magnesium palmitate (C32H62MgO4). The PhEur 2005 describes magnesium 
stearate as a mixture of magnesium salts of different fatty acids consisting mainly of stearic 
acid and palmitic acid and in minor proportions other fatty acids. 
5. Structural Formula: 
[CH3(CH2)16COO]2Mg 
6. Functional Category: 
Tablet and capsule lubricant. 
7. Applications in Pharmaceutical Formulation or Technology: 
Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical 
formulations. It is primarily used as a lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0% w/w. It is also used in barrier creams. 
8. Description: 
Magnesium stearate is a very fine, light white, precipitated or milled, impalpable 
powder of low bulk density, having a faint odor of stearic acid and a characteristic taste. The 
powder is greasy to the touch and readily adheres to the skin. 
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9. Typical Properties 
Crystalline forms: high-purity magnesium stearate has been isolated as a      
trihydrate, a dihydrate, and an anhydrate. 
Density (bulk): 0.159 g/cm3 
Density (tapped): 0.286 g/cm3 
Density (true): 1.092 g/cm3 
Flash point: 250°C 
Flowability: poorly flowing, cohesive powder. 
Melting range: 
• 117–150°C (commercial samples); 
• 126–130°C (high purity magnesium stearate). 
Solubility: practically insoluble in ethanol, ethanol (95%), ether and water; s
 lightly soluble in warm benzene and warm ethanol (95%). 
Specific surface area: 1.6–14.8 m2/g 
10. Stability and Storage Conditions: 
Magnesium stearate is stable and should be stored in a well-closed container in a cool, 
dry place. 
11. Incompatibilities: 
Incompatible with strong acids, alkalis, and iron salts. Avoid mixing with strong 
oxidizing materials. Magnesium stearate cannot be used in products containing aspirin,    
some vitamins, and most alkaloidal salts. 
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2.3.7 TALC: 
1. Nonproprietary Names 
• BP: Purified talc 
• JP: Talc 
• PhEur: Talcum 
• USP: Talc 
2. Synonyms: 
Altalc; E553b; hydrous magnesium calcium silicate; hydrous magnesium silicate; 
Luzenac Pharma; magnesium hydrogen metasilicate; Magsil Osmanthus; Magsil Star; 
powdered talc; purified French chalk; Purtalc; soapstone; steatite; Superiore. 
3. Chemical Name and CAS Registry Number: 
Talc [14807-96-6] 
4. Empirical Formula and Molecular Weight: 
Talc is a purified, hydrated, magnesium silicate, approximating to the formula Mg6 
(Si2O5)4(OH)4. It may contain small, variable amounts of aluminum silicate and iron. 
5. Functional Category; 
Anticaking agent; glidant; tablet and capsule diluent; tablet and capsule lubricant. 
6. Applications in Pharmaceutical Formulation or Technology: 
Talc was once widely used in oral solid dosage formulations as a lubricant and 
diluent, although today it is less commonly used. However, it is widely used as a      
dissolution retardant in the development of controlled-release products. Talc is also used as    
a lubricant in tablet formulations; in a novel powder coating for extended-release pellets;     
and as an adsorbant. 
In topical preparations, talc is used as a dusting powder, although it should not be 
used to dust surgical gloves. Talc is a natural material; it may therefore frequently contain 
microorganisms and should be sterilized when used as a dusting powder. 
Talc is additionally used to clarify liquids and is also used in cosmetics and food products, 
mainly for its lubricant properties. 
7. Description: 
  Talc is a very fine, white to grayish-white, odorless, impalpable, unctuous,      
crystalline powder. It adheres readily to the skin and is soft to the touch and free from 
grittiness. 
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8. Typical Properties: 
Acidity/alkalinity: pH = 7–10 for a 20% w/v aqueous dispersion. 
Hardness (Mohs): 1.0–1.5 
Moisture content: talc absorbs insignificant amounts of water at 25°C and relative 
humidities up to about 90%. 
Particle size distribution: varies with the source and grade of material. Two typical 
grades are ≥99% through a 74 µm (#200 mesh) or ≥99% through a 44 µm              
(#325 mesh). 
Refractive index: n20D = 1.54–1.59 
Solubility: practically insoluble in dilute acids and alkalis, organic solvents, and 
water. 
Specific gravity: 2.7–2.8 
Specific surface area: 2.41–2.42 m2/g 
9. Stability and Storage Conditions: 
Talc is a stable material and may be sterilized by heating at 160°C for not less than     
1 hour. It may also be sterilized by exposure to ethylene oxide or gamma irradiation. 
Talc should be stored in a well-closed container in a cool, dry place. 
10. Incompatibilities: 
Incompatible with quaternary ammonium compounds. 
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3. AIM AND OBJESTIVES 
 
AIM OF THE STUDY 
The primary Aim of the study is modified release of drug delivery is to ensure      
safety and to improve efficacy of drugs as well as patient compliance. If the drug is given     
in conventional dosage form, it has to be administered several times a day to produce the 
desired therapeutic effect. Because of the frequent dosing fluctuation in plasma drug level 
occurs. If the drug dosing interval is not in accordance with biological half-life large peaks 
and valleys are possible with time-drug concentration in blood curve. The pronounced 
fluctuations resulting from the conventional drug administration are likely to yield period of 
no therapeutic effect when drug concentration fall below minimum therapeutic level.  
 
 
OBJECTIVE OF THE STUDY 
The main objective of present study is to develop Bilayer tablets of Sumatriptan 
succinate for the treatment Migrainic attacks.  
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4. PLAN OF WORK 
 Literature survey.  
 Materials and equipments. 
   Preformulation studies. 
 Characterization of Drug. 
• Appearance 
• Melting Point Determination. 
• Solubility Study. 
 Identification of Drug 
• FTIR. 
• UV Spectral analysis 
 Drug - Polymers Interaction Studies. 
• Differential Scanning Calorimetry (DSC) Analysis.  
• Fourier transforms Infra-Red (FTIR) Spectroscopy Study. 
 Preparation and Evaluation of Granules. 
• Bulk density. 
• Tapped density. 
• Carr’s Compressibility Index. 
• Hausner’s ratio. 
• Angle of repose. 
 Formulation of Bilayer Tablets. 
 Evaluation of Tablets. 
 Physico-Chemical Properties of Tablets. 
• Appearance. 
• Size and Thickness. 
• Hardness. 
• Friability. 
• Weight variation. 
• Drug content. 
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 In-vitro Drug Release Studies. 
 Kinetics of In-vitro drug release 
 Stability Studies. 
 Results and Discussion. 
 Summary and Conclusion. 
 Future Prospects. 
 Bibliography
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5. MATERIALS AND EQUIPMENTS 
5.1 List of Materials used with Sources: 
Table 2: List of Materials and their Suppliers. 
S. 
No. 
Name of Material Supplied by 
1 Sumatriptan succinate SAVAN PHARMACEUTICALS 
2 Sodium alginate SAVAN PHARMACEUTICALS 
3 Xanthan gum SAVAN PHARMACEUTICALS 
4 Guar gum SAVAN PHARMACEUTICALS 
5 Magnesium stearate SAVAN PHARMACEUTICALS 
6 Microcrystalline cellulose SAVAN PHARMACEUTICALS 
7 Starch SAVAN PHARMACEUTICALS 
8 Talc SAVAN PHARMACEUTICALS 
9 Crospovidone SAVAN PHARMACEUTICALS 
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5.2 List of Equipments used with model: 
Table 3: List of equipments with their make and model.  
S. 
No. 
Name of the equipment Source 
1 Electronic balance BL- 220H, Shimadzu Corporation , Japan 
2 UV-Visible spectrophotometer Shimadzu-1700, Shimadzu Corporation, Japan 
3 Tablet Punching Machine Remik Equipments, Ahmedabad. 
4 Fourier-transformed infrared(FTIR) Spectrophotometer 
Perkin elmer-Pharmaspec-
1,Japan. 
5 Tap density apparatus Indolabs, Chennai 
6 Dissolution test apparatus ElectroLab,  Mumbai 
7 Digital pH meter Elico Scientifics-LI 612,  Mumbai. 
8 Hot air oven Lawrence & Mayo. 
9 Vernier Caliper Mitutoyo, Japan. 
10 Friability apparatus Veego corporation 
11 Melting point test apparatus Precision scientific co., Chennai 
12 Monsanto Hardness tester Secor India. 
 
 
  
 
 
 
 
 
 
 
 
 
 
CHAPTER-6 
 
PREFORMULATION 
STUDIES 
 
 
 
PREFORMULATION STUDIES                                                                                    CHAPTER-6 
 
 
ADHIPARASAKTHI COLLEGE OF PHARMACY  69 
 
 
6. PREFORMULATION STUDIES 
6.1 CHARACTERIZATION OF DRUG:       
6.1.1 Colour and Appearance:                 (United State Pharmacopoeia, 2007) 
    The sample was observed visually. 
6.1.2 Melting Point:  
Melting point of drug was determined by Melting point test apparatus. 
6.1.3 pH Determination:  
A 2 % saturated solution of Sumatriptan succinate was prepared in distilled water and 
pH was measured by digital pH meter. 
6.1.4 Solubility:                                              (Indian Pharmacopoeia, 1996) 
            Solubility study was carried out as per the I.P.2007. In this maximum amount of 
solvent required to dissolve the solute was determined.  
6.1.5 Spectral Analysis of Sumatriptan succinate:     
6.1.5.1 UV Spectral Analysis of Sumatriptan succinate: 
6.1.5.1.1 UV Spectral Analysis of Sumatriptan succinate in 0.1N HCl: 
6.1.5.1.1.1 Determination of absorption maximum in 0.1N HCl: 
The absorption maximum of the standard solution was scanned between                  
200-400 nm regions on Shimadzu-1700 Pharmaspec UV-VISIBLE spectrophotometer. The 
absorption maximum obtained with the substance being examined corresponds in position 
and relative intensity to those in the reference spectrum represented. 
 6.1.5.1.1.2 Preparation of Standard Curve of Sumatriptan succinate in 0.1N HCl: 
Preparation of 0.1N HCl: 
0.1N HCl was prepared by diluting 8.5 ml of hydrochloric acid in 1000 ml of distilled 
water. 
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Procedure: 
Accurately weighed 100mg of Sumatriptan succinate was dissolved in little      
quantity of 0.1NHydrochloric acid and volume was adjusted to 100ml with the same to 
prepare a standard solution having concentration of 1000µg/ml. From this above solution 1   
ml was pipette out and transferred to a 10 ml volumetric flask and the volume was adjusted 
with 0.1NHydrochloric acid to a concentration of 100µg/ml. From this stock solution, 
aliquots of 0.2, 0.4, 0.6, 0.8 and 1.0 ml was pipette out and transferred to 10 ml volumetric 
flasks and final volume was made with 0.1NHydrochloric acid for giving concentrations 
ranged from 2.0 to 10 µg/ml. The absorbance of these solutions was measured in UV-   
Visible spectrometer at 227nm using 0.1NHydrochloric acid as blank.  
Assay of Sumatriptan succinate: 
Accurately weighed 25 mg of Sumatriptan succinate was dissolved in little quantity    
of 0.1N HCl and volume was adjusted to 25 ml with the same to prepare standard solution 
and the volume was adjusted with 0.1N HCl to get a concentration of 1000µg/ml. From      
this stock solution, 0.1ml was pipette out and transferred to 10 ml volumetric flask and     
final volume was adjusted with 0.1N HCl. Absorbance values of these solutions were 
measured against blank at 227 nm using UV-Visible spectrophotometer. The percentage 
purity of drug    was calculated by using calibration graph method. 
6.1.5.1.2 UV Spectral Analysis of Sumatriptan succinate in pH 6.8 phosphate                           
buffer:    
6.1.5.1.2.1 Determination of absorption maximum in pH 6.8 phosphate buffer: 
The absorption maximum of the standard solution was scanned between 200-400     
nm regions on Shimadzu-1700 Pharmaspec UV-VISIBLE spectrophotometer. The    
absorption maximum obtained with the substance being examined corresponds in position 
and relative intensity to those in the reference spectrum represented. 
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6.1.5.1.2.2 Preparation of Standard Curve of Sumatriptan succinate in pH 6.8    
phosphate buffer: 
Preparation of pH 6.8 phosphate buffer : 
pH 6.8 phosphate buffer:  
50ml of 0.2M potassium dihydrogen phosphate was taken in 200ml volumetric     
flask, to which 22.4ml of 0.2M sodium hydroxide solution was added and the volume was 
made upto the mark with distilled water. 
0.2M potassium dihydrogen phosphate:  
27.218 gm of potassium dihydrogen phosphate was added to 1000ml volumetric    
flask containing distilled water and the volume was made upto the mark with distilled     
water. 
0.2M Sodium Hydroxide:  
8gm of Sodium Hydroxide was taken in a 1000ml volumetric flask containing 
distilled water and volume was made upto the mark with distilled water. 
Procedure:  
Accurately weighed 100mg of Sumatriptan succinate was dissolved in little      
quantity of pH 6.8 phosphate buffer and volume was adjusted to 100ml with the same to 
prepare a standard solution having concentration of 1000µg/ml. From this above solution 1    
ml was pipette out and transferred to a 10 ml volumetric flask and the volume was adjusted 
with pH 6.8 phosphate buffer to a concentration of 100µg/ml. From this stock solution, 
aliquots of 0.2, 0.4, 0.6, 0.8 and 1.0 ml was pipette out and transferred to 10 ml volumetric 
flasks and final volume was made with pH 6.8 phosphate buffer for giving concentrations 
ranged from 2.0 to 10 µg/ml. The absorbance of these solutions was measured in UV-     
Visible spectrometer at 227nm using pH 6.8 phosphate buffer as blank.  
 
6.1.6 Infrared Spectrum:                                                      (Robert M. Silverstein, 2003) 
The infrared spectrum of Sumatriptan succinate was recorded by using FTIR      
(Perkin elmer-Pharmaspec-1) instrument. A small quantity of sample was mixed with       
equal quantity of potassium bromide and placed in sample cell to record its IR spectra.  
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6.1.7 LOSS ON DRYING:                                       (Indian Pharmacopoeia, 2007)           
Loss on drying is the loss of weight expressed as percentage w/w resulting from 
volatile matter of any kind that can be driven off under specified condition. The test can be 
carried out on the well mixed sample of the substance. 
 
         Initial weight of substance – Final weight of substance 
Loss on drying =       
                                           Initial weight of substance 
 
6.2 DRUG - POLYMERS COMPATABILITY STUDIES: 
Drug polymers studies holds great importance in designing a formulation In drug 
formulation it is essential to evaluate the possible interactions between the active principle 
and the polymers, as the choice of the polymers should be performed in relation to the drug 
delivery, to their compatibility with the same drug and to the stability of the final product. 
6.2.1 Fourier Transform Infra-Red Spectroscopy (FTIR) Study:  
                    (Robert M. Silverstein, 2003; Becket A. H., 2005) 
Sumatriptan succinate powder was mixed with various polymers in the ratio of 1:1. 
Then, afterwards the samples were scanned with FTIR (Perkin Elmer-Pharmaspec-1) over      
a wave number range of 4000-400 cm-1. 
 6.2.2 Differential Scanning Calorimetry Study (DSC):                (Jain N. K., 2006)        
Sumatriptan succinate powder was mixed with various polymers in the ratio of 1:1. 
The mixture of drug with polymers to maximize the like hood of obscuring an interaction. 
Mixture should be examined under Nitrogen to eliminate oxidative and pyrolytic effect at a 
standard heating rate (2, 5 or 100C/minute) on DSC. Over a temperature range, which will 
encompass any thermal changes due to the mixture of drug with polymers thermograms of 
pure drug are used as a reference.      
Appearance or disappearance of one or more peaks in thermograms of drug with 
polymer are considered as an indication of interaction. 
 
×100 
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6.3 PREPARATION AND EVALUATION OF POWDER BLENDS:  
6.3.1 PREPARATION OF POWDER BLENDS: 
         All ingredients were weighed and passed through mesh #40 separately. The drug and 
polymer were blended first in mortar and pestle then the remaining ingredients are added in 
that and blended for 20 min. Finally the blend is passed through mesh # 20 and used for 
evaluation of flow characteristics.       
6.3.2 EVALUATION OF MICROMERITIC PROPERTIES OF POWDERS 
 Angle of Repose:      (Aulton M.E., 2007; Sinko P. J., 2006; Ansel S. C.,) 
                           The angle of repose was determined by the funnel method. The 
accurately weighed (10 gms) granules were taken in a funnel. The height of the funnel was 
adjusted in such a way that the tip of the funnel just touched the apex of the heap of      
granules. The granules were allowed to flow through the funnel freely onto a clean surface. 
The diameter of the granules cone was measured and angle of repose was calculated using    
the following equation:    
       tan θ = h/r 
Where h is the height of granules cone and r is the radius of the granules cone.  
Table 4: Relationship between Angle of Repose (θ) and Flowability 
S. No. Angle of repose(θ) Flowability 
1 <20 Excellent 
2 20 – 30 Good 
3 30 – 35 Passable 
4 >40 Very poor 
 

 Bulk Density and Tapped Bulk Density:  
                        An accurately weighed (10 gms) granules from each formula was lightly 
shaken to break any agglomerates formed and it was introduced into a measuring cylinder. 
The volume occupied by the granules was measured which give bulk volume. The      
measuring cylinder was tapped until no further change in volume was noted which gave                        
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the tapped volume. Both Bulk Density (BD) and Tapped Bulk Density (TBD) of granules 
were determined using the following formulae. 
BD = Weight of the granules/Volume of the granules 
TBD = Weight of the granules/Tapped volume of the granules 
 Carr’s Compressibility Index: 
The compressibility index of the granules was determined using following Carr’s 
compressibility index formula. 
                   Carr’s Compressibility Index (%) = [(TBD-LBD)/ TBD] x100 
Relationship   between % compressibility and flowability is shown in the Table 5. 
    Table 5: Relationship between % Compressibility and Flowability 
S. No. % Compressibility Flowability 
1 5-15 Excellent 
2 12-16 Good 
3 18-21 Fair Passable 
4 23-35 poor 
5 33-38 Very poor 
6 >40 Very very poor 
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 Hausner’s ratio: 
Hausner’s ratio is the ratio between tapped density and bulk density. Hausner’s     
ratio less than 1.25 indicates good flow properties while Hausner’s ratio greater than 1.25 
shows poor flow of granules. 
Table 6: Relationship between Hausner’s ratio and Flowability 
S. No. Hausner’s ratio Flow Property 
1 0.0 - 1.25 Free flow 
2 1.25 - 1.6 Cohesive flow 
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7. FORMULATION OF BILAYER TABLETS 
  
 
7.1 Formulation development of Sumatriptan Succinate IR layer 
 
Table 7: Formulation development of Sumatriptan Succinate IR layer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.No Ingredients Formula (mg) 
1. Sumatriptane Succinate 50 
2. Crosspovidone 5 
3. Methyl crystalline cellulose 20 
4. Mannitol 20 
5 Magnesium Stearate 3 
6 Talc 2 
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7.2 Formulation development of Sumatriptan Succinate SR layer 
Table 8: Formulation development of Sumatriptan Succinate SR layer 
 
 
 
 
 
 
 
 
Excipients F1 F2 F3 F4 F5 F6 F7 F8 F9 
Sumatriptane 
Succinate 
200 200 200 200 200 200 200 200 200 
Xanthan Gum 50   100   25 25  
Guar gum  50   100  25  25 
Sodium 
alginate 
  50   100  25 25 
Starch 40 40 40 40 40 40 40 40 40 
Talc 3 3 3 3 3 3 3 3 3 
Mannitol 94 94 94 44 44 44 94 94 94 
Megnisium 
stearate 
5 5 5 5 5 5 5 5 5 
PVP (2%) 8 8 8 8 8 8 8 8 8 
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7.3 FORMULATION AND CHARACTERIZATION OF BILAYER TABLETS:   
            (Preeti et al 2011) 
The bilayer tablets of Sumatriptan succinate were prepared by the direct compression 
method. The drug and polymers for both IR and SR layer were passed through a # 60 sieve 
before their use in the formulation. 
Formulation of the IR Layer:  
The IR ingredients (Table 7) were accurately weighed and added into the blender in 
ascending order. The powder mix was blended for 20 min. to obtain uniform distribution of 
the drug in formulation and subjected for preformulation studies. 
Formulation of the SR Layer 
The SR ingredients (Table 8) were accurately weighed and added into the blender in 
ascending order. The powder mix was blended for 20 min. to obtain uniform distribution of 
the drug in formulation and subjected for preformulation studies. 
Compression of Bilayer Tablet 
In the present study bilayer tablet was prepared manually using single station 
punching machine. Accurately weighed amount of SR powder mix was fed manually into die 
cavity. SR layer was compressed at mild compression force. After that accurately weighed IR 
powder mix was manually fed into the die on SR layer and compressed using 8-mm flat 
punches (Rimek mini press-1 Karnavati Engineering Ltd, Gujarat). 
 
7.4 Dose Calculation:  
For sustained drug release up to 24 hr, the immediate dose of drug was calculated 
from total dose of Sumatriptan succinate extended release tablet. 
Dt = Dose (1 + 0.693 × t/t1/2) 
Where,  
Dt = Total dose, 
Dose = Immediate release dose, 
t = Total time period for which sustained release is required, 
t1/2 = Half-life of drug. 
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8. EVALUATION OF BILAYER TABLETS 
 Evaluation of Tablets: 
 Physico-Chemical Properties of Tablets. 
 Appearance 
 Thickness 
 Hardness 
 Friability 
 Weight variation 
 Drug content 
 In-vitro Drug Release. 
 Kinetics of in-vitro drug release. 
 Stability Studies. 
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 8.1 Physico-Chemical Properties of Tablets:  
8.1.1 Appearance :                                                      (Lachman L., 1991; Gilbert S., 2007) 
    The tablets were visually observed for any capping, chipping and lamination. 
8.1.2 Size and Thickness:  
The size and thickness of tablet can vary with no change in weight due to        
difference in Density of granulation, the pressure applied to the tablets and speed of the    
tablet compression machine. The thickness of the tablets was determined using a Vernier 
caliper. Three tablets from each type of formulation were used and average values were 
calculated. 
8.1.3 Hardness:  
There is a certain requirement of hardness in tablets so as to withstand the    
mechanical shocks during handling, manufacturing, packaging and shipping. Hardness     
tester (Monsanto tester) was used to measure hardness of tablets. The tablet was held along 
its oblong axis in between the two jaws of the tester. At this point, reading should be taken    
as a zero kg/cm2. Then constant force was applied by rotating the knob until the tablet 
fractured. The value at this point was noted in kg/cm2.  
8.1.4 Friability:  
Friability is the measure of tablet strength. This test subjects a number of tablets to    
the combined effect of shock abrasion by utilizing a plastic chamber which revolves at a 
speed of 25 rpm for four minutes, dropping the tablets to a distance of 6 inches in each 
revolution. A sample of pre-weighed tablets was placed in Roche friabilator which was     
then operated for 100 revolutions. The tablets were then dedusted and reweighed. Percent 
friability (% F) was calculated as follows,    
% Friability = (Initial weight - Final weight / Initial weight) x 100. 
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8.1.5 Weight Variation:                                       (Indian Pharmacopoeia, 2007)     
The weight variation test is done by taking 20 tablets randomly and they were 
weighed individually. The composite weight divided by 20, provides an average weight of 
tablet. Not more than two of the individual weight deviates from the average weight by % 
deviation allowed and none should deviate by more than twice its percentage.  
Table 9: Specifications of % weight variation allowed in Tablets as per Indian 
Pharmacopoeia 
Average Weight of Tablet %  Deviation allowed 
80 mg or less 10 
More than 80 mg but less that 250 mg 7.5 
250 mg  or more 5 
 
8.1.6 Drug Content:  
    20 tablets of each formulation taken and amount of drug present in each tablet was 
determined. Powder equivalent to 25 mg was taken and added in 25 ml of 0.1N HCl     
followed by stirring for 10 min. This was filtered through a 0.45 µ membrane filter, diluted    
to get 10 µg/ml concentration and absorbance of resultant solution was measured by UV at 
227nm using 0.1N HCl. 
8.2 In-vitro Dissolution of Tablets: 
The release rate of sumatriptan succinate from bilayer tablets was determined using 
USP Dissolution Testing Apparatus type-I (basket method; Veego Scientific VDA-8DR, 
Mumbai, India). A sample (5 ml) of the solution was withdrawn from the dissolution 
apparatus and the samples were replaced with fresh dissolution medium. The samples were 
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filtered through a 0.45µ membrane filter and diluted to a suitable concentration with 
respected medium. Absorbance of these solutions was measured at 227nm using a    
Shimadzu-1700 Pharmaspec UV-VISIBLE spectrophotometer. For each formulation, the 
experiments were carried out in triplicate. The release data were calculated by using PCP 
disso V3 software. 
IN-VITRO DISSOLUTION STUDIES: 
 
For Sumatriptan Succinate IR Layer: 
Medium :  900 ml of 0.1N Hydrochloric acid  
RPM  :  50             
Apparatus :  Basket         
Time  :  15,30,45,60,120 minutes        
Wave Length :  227 nm           
Temperature :  370C ± 0.50C 
 
For Sumatriptan Succinate SR Layer: 
Medium  : 900 ml of buffer pH 6.8   
RPM               : 50 
Apparatus    : Basket 
Time               :  4th, 6th, 8th, 12th,24 th Hours. 
Wave Length :  227 nm           
Temperature   : 370 C ± 0.50C  
 
 8.3 Kinetics of In-vitro Drug Release:               (Brahmankar D.M., 2006) 
To study the release kinetics of In-vitro drug release, data was applied to kinetic 
models such as zero order, first order, Higuchi and Korsmeyer- Peppas. 
 Zero order:  
K0 - zero-order rate constant expressed in units of concentration/time, t - time in hrs. 
 First order:  
C = K0t                                                                                                               
LogC = LogC0 – Kt / 2.303                                                                             
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Where   C0 - is the initial concentration of drug, K - first order constant, t - time in hrs.  
 Higuchi:  
Where   Qt - amount of the release drug in time t, K- kinetic constant, t- time in hrs. 
 Korsmeyer Peppas:     
Where   Mt - represents amount of the released drug at time t,  
             M∞- is the overall amount of the drug (whole dose) released after 24 hrs  
               K- is the diffusional characteristic of drug/ polymer system constant  
                n- is a diffusional exponent that characterizes the mechanism of release of drug.  
8.4 STABILITY STUDIES:                                                        (Janes T., 2000)                            
The purpose of stability testing is to provide evidence on how the quality of a drug 
substance or drug product varies with time under the influence of a variety of      
environmental factors such as temperature, humidity and light, enabling recommended 
storage conditions, re-test periods and shelf-lives. Generally, the observation of the rate at 
which the product degrades under normal room temperature requires a long time. To avoid 
this undesirable delay, the principles of accelerated stability studies are adopted. The 
International Conference on Harmonization (ICH) Guidelines titled “Stability testing of    
New Drug Substances and Products” describes the stability test requirements for drug 
registration application in the European Union, Japan and the States of America. 
Stability studies were carried out at 40°C / 75% RH for the optimized formulation for 
3 months. The tablets were stored at 40°C/75% RH in closed high density polyethylene 
bottles for 3 months. The samples were withdrawn after periods of 1, 2 and 3 months. The 
samples were analyzed for its hardness, drug content and In-vitro drug release. 
 
 
Mt / M∞ = Kt n                                                                                             
Qt = Kt
1/2
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9. RESULTS AND DISCUSSION 
9.1 CHARACTERIZATION OF DRUG: 
 9.1.1 Colour and Appearance: 
The drug (Sumatriptan succinate) colour is “White to almost white powder” as      
same as the reported reference. 
9.1.2 Melting Point: 
The Melting point of Sumatriptan succinate was found to be 169 ± 1.081.  The 
reported melting point of Sumatriptan succinate is 166-1710C. Hence, observed values are 
complies with USP. 
9.1.3 Solubility study: 
Freely soluble in water, sparingly soluble in methanol, practically insoluble in 
methylene chloride. 
 9.1.4 SPECTROSCOPIC STUDIES: 
 9.1.4.1 UV Spectroscopy: 
 9.1.4.1.1 Determination of λmax and Preparation of Calibration Curve of     
Sumatriptan succinate by using 0.1N HCl: 
UV absorption spectrum of Sumatriptan succinate in 0.1N HCl shows λmax at 
227nm. Absorbance obtained for various concentrations of Sumatriptan succinate in 0.1N 
HCl are given in Table 10. The graph of absorbance versus concentration for Sumatriptan 
succinate was found to be linear in the concentration range of 2-10 µg /ml. The drug obeys 
Beer- Lambert’s law in the range of 2-10 µg /ml. 
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Fig 1: Absorption maximum of Sumatriptan succinate in 0.1N HCl 
 
Table 10: Concentration and Absorbance data for Calibration Curve of Sumatriptan 
succinate in 0.1 N HCl: 
S. No. Concentrations(µg/ml) Absorbance at 227nm. 
1 0 0 
2 2 0.135 
3 4 0.251 
4 6 0.367 
5 8 0.480 
6 10 0.594 
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Fig 2: Calibration Curve of Sumatriptan succinate in 0.1 N HCl 
 
UV Spectroscopy: 
 9.1.4.1.2 Determination of λmax and Preparation of Calibration Curve of Sumatriptan 
succinate by using pH 6.8 phosphate buffer: 
UV absorption spectrum of Sumatriptan succinate in pH 6.8 phosphate buffer        
shows λmax at 227.8nm. Absorbance obtained for various concentrations of Sumatriptan 
succinate in pH 6.8 phosphate buffer are given in Table 11. The graph of absorbance       
versus concentration for Sumatriptan succinate was found to be linear in the concentration 
range of 2-10 µg /ml. The drug obeys Beer- Lambert’s law in the range of 2-10 µg /ml. 
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Fig 3: Absorption maximum of Sumatriptan succinate in pH 6.8 phosphate buffer 
 
Table 11: Concentration and Absorbance data for Calibration Curve of Sumatriptan 
succinate in pH 6.8 Phosphate buffer: 
S. No. Concentrations(µg/ml) Absorbance at 227.8nm. 
1 0 0 
2 2 0.145 
3 4 0.305 
4 6 0.445 
5 8 0.604 
6 10 0.734 
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 Fig 4: Calibration Curve of Sumatriptan succinate by using pH 6.8 phosphate 
buffer: 
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9.1.4.2 Fourier Transform Infra-Red Spectroscopy (FTIR): 
The IR spectrum of Sumatriptan succinate is shown in figure 5. The Interpretation of IR 
frequencies are show in Table 12. 
 
 
Fig 5: FTIR spectra of Sumatriptan succinate pure drug: 
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Interpretation of FTIR Spectrum: 
Table shows the peaks observed at different wave numbers and the functional group 
associated with these peaks. The major peaks are identical to functional group of Sumatriptan 
succinate. Hence, the sample was confirmed as Sumatriptan succinate.  
 
Table 12: Characteristic frequencies in IR Spectrum of Sumatriptan succinate 
Functional groups Wave No. (cm-1) 
C-H (Aromatic) 3088.77 
C=C (Aromatic) 1556.29 
C-C (Loop) 1428.49 
N-H (Stretching) 3369.75 
C-N 1341.00 
S=O 1135.22 
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9.2 DRUG - POLYMERS COMPATIBILITY STUDIES: 
 9.2.1 Fourier Transform Infra-Red Spectroscopy (FTIR): 
 
Fig 6: FTIR spectroscopy of guar gum 
                             
Fig 7: FTIR spectroscopy of xanthan gum 
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Fig 8: FTIR spectroscopy of crospovidone  
Fig 9: FTIR spectroscopy of best formulation (F7) 
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Table 13: Characteristic Frequencies in IR Spectrum of Sumatriptan succinate 
formulation 
Functional groups Wave No. (cm-1) 
C-H (Aromatic) 2950.93 
C=C (Aromatic) 1558.31 
C-C (Loop) 1419.24 
N-H (Stretching) 3369.75 
C-N 1338.89 
S=O 1143.64 
 
From the above figure, it can be seen that, the major functional group peaks      
observed in spectra of Sumatriptan succinate with guar gum, xanthan gum remains 
unchanged as compared with spectra of sumatriptan succinate. So from the above IR     
spectra it can be observed that there is no interaction between Sumatriptan succinate and 
polymers used in the formulations. 
 
 
 
 
 
 
 
 
 
RESULTS AND DISCUSSION                                                                                      CHAPTER-9 
 
 
ADHIPARASAKTHI COLLEGE OF PHARMACY  94 
 
 
9.2.2 Differential Scanning Calorimetry (DSC): 
 
 
Fig 10: Thermogram of SUMATRIPTAN SUCCINATE 
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Fig 11: Thermogram of SUMATRIPTAN SUCCINATE + GUAR GUM
Fig 12: Thermogram of SUMATRIPTAN SUCCINATE + XANTHAN GUM
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The results of DSC studies are given in above figure. Pure Sumatriptan succinate     
showed sharp endotherm at 166°C corresponding to its melting point. There was no 
appreciable change in the melting endotherms of Sumatriptan succinate with Guar gum       
and Sumatriptan succinate with Xanthan gum as compared to the thermogram of     
Sumatriptan succinate. So, it could be concluded that there is no interaction between 
Sumatriptan succinate and Polymers used in the formulations. 
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9.3 EVALUATION OF MICROMERITIC PROPERTIES OF POWDER BLENDS: 
Table 14: Preformulation parameters of Sumatriptan Succinate SR granules: 
 
Formulation 
Bulk density 
(gm/ml) 
Tapped 
density 
(gm/ml) 
Angle of 
repose (θ) 
(0) 
Carr’s index 
(%) 
Hausner’s 
ratio 
F1 0.43±0.007 0.59±0.006 21.45±1.7 17.34±1.7 1.634±1.2 
F2 0.41±0.004 0.62±0.009 27.52±0.4 19.54±0.8 1.382±0.7 
F3 0.38±0.009 0.53±0.007 34.62±1.5 23.65±1.1 1.442±1.0 
F4 0.53±0.005 0.59±0.004 31.43±0.5 21.45±0.9 1.238±1.3 
F5 0.45±0.007 0.54±0.005 24.65±1.3 20.61±1.8 1.327±1.3 
F6 0.47±0.005 0.58±0.004 27.95±1.4 25.49±1.3 1.643±0.9 
F7 0.52±0.008 0.61±0.006 24.27±1.6 19.62±0.9 1.225±0.7 
F8 0.49±0.006 0.54±0.003 31.48±0.9 17.50±1.2 1.505±1.2 
F9 0.36±0.009 0.58±0.007 26.65±1.0 22.48±1.7 1.605±0.4 
                       All the values are expressed as a mean ± SD., n = 3 
 
Table 15: Preformulation parameters of Sumatriptane Succinate IR layer: 
 
Preformulation parameters Formulation 
Bulk density (gm/ml) 0.42±0.008 
Tapped density (gm/ml) 0.54±0.005 
Angle of repose (θ)0 24.11±1.4 
Carr’s index (%) 22.42±1.8 
Hausner’s ratio 1.7±1.2 
                All the values are expressed as a mean ± SD., n = 3 
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9.3.1 Angle of repose: 
 The results for angle of repose are recorded in Table 14, 15. Angle of repose ranged 
from 21.45±1.7 to 34.62±1.5. The flow properties of granules in all formulations exhibit      
good flow. 
9.3.2 Bulk density and Tapped bulk density:  
 The results are shown in Table 14, 15. The values of BD and TBD were found to be in 
the range from 0.36±0.009 to 0.53±0.005 gm/cc and 0.53±0.005 to 0.62±0.009 gm/ml 
respectively. So, it shows that all formulations having good flow properties and      
packability.  
9.3.3 Carr’s Compressibility Index:  
 The results for Carr’s Compressibility Index are recorded in Table 14, 15. The      
Carr’s Compressibility Index were in the range from 17.34±1.7 to 25.49±1.3%. This    
indicates good flow properties of granules. 
9.3.4 Hausner’s ratio:  
The results were summarized in Table 14, 15. The Hausner’s ratios were found in     
the range from 1.225±0.7 to 1.643±0.9. So it indicates good flow properties. 
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9.4 EVALUATION OF TABLETS: 
 9.4.1 Evaluation of Physico-chemical properties of tablets  
Table 16: Physico-Chemical Properties of Tablets: 
   *All the values are expressed as a mean ± SD., n = 3 
** All the values are expressed as a mean ± SD., n = 6 
9.4.1.1 Appearance:  
The tablets were observed visually and did not show any defects such as capping, 
chipping and lamination after punching.    
9.4.1.2 Thickness:  
The thickness of formulations ranged from 6.8±0.2 mm to 7.2±0.2mm. The values     
are recorded in Table 16. 
Formulation 
Wt.variation 
(%) 
Friability* 
(%) 
Hardness** 
(kg/cm2) 
Thickness** 
(mm) 
Assay* 
(%) 
F1 0.6012 0.25±0.15 5.5±0.7 6.9±0.9 99.49±0.17 
F2 0.5988 0.34±0.19 6.0±0.9 6.8±0.2 100.16±0.16 
F3 0.6006 0.26±0.17 6.5±0.2 7.0±0.6 99.88±0.25 
F4 0.6018 0.12±0.12 9.3±0.7 7.1±0.4 100.5±0.17 
F5 0.6005 0.19±0.15 8.6±0.4 6.9±0.2 98.36±0.25 
F6 0.5996 0.32±0.13 6.7±0.8 6.8±0.8 98.98±0.16 
F7 0.6005 0.28±0.19 6.8±1.2 7.0±0.5 99.60±0.25 
F8 0.6008 0.26±0.12 8.4±1.8 6.9±0.6 99.09±0.25 
F9 0.6001 0.15±0.16 9.4±0.9 7.2±0.2 100.72±0.19 
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9.4.1.3 Weight Variation:  
 The percentage deviation from average tablet weight for all the formulations      
ranged from 499±1.2 to 501±1.5mg. The results are within the specified limits and showed in 
Table 16. Hence all formulations complied with the test for weight variation as per IP. 
9.4.1.4 Hardness:  
The results of Hardness of tablets were recorded in Table 16. It was found that the 
values are ranged from 5.5±0.7 to 9.4±0.9 kg/cm2. Hardness values were satisfactory and 
indicated good mechanical strength of tablets. 
9.4.1.5 Friability:  
The Percentage Friability of all the formulations showed in Table 16. The results      
are ranged from 0.12±0.12 to 0.34±0.19%. So, the percentage loss of Friability of all the 
formulations was found to be less than 1 %. 
9.4.1.6 Drug content: 
  Drug content was found to be uniform among different batches of tablets and ranged 
from 98.4±0.5 to 100.7±0.9%. These results showed that the all formulations having 
percentage drug content within the specified limits as per USP. 
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9.4.2 IN-VITRO DISSOLUTION STUDIES: 
9.4.2.1 In-vitro dissolution profile: 
Dissolution profile (% drug release) of formulations F1, F2, F3. 
 
     Table 17: In-vitro dissolution data of Formulation F1, F2, F3  
S.No MEDIUM TIME(hrs) Cumulative % drug release of 
F1 F2 F3 
1 
0.1N HCl 
0 0.00 0.00 0.00 
2 0.15 13.1069 10.6103 11.2344 
3 0.30 19.2846 19.9724 19.3482 
4 0.45 20.7823 21.8448 20.5965 
5 1 21.7832 22.3954 22.5879 
6 2 23.8459 23.8674 24.7963 
7 
pH 6.8 
phosphate 
buffer 
4 28.8401 29.8935 36.6958 
8 6 36.9757 35.7835 43.6383 
9 8 43.8476 43.8123 52.5643 
10 12 70.4164 66.8263 63.9698 
11 24 95.7068 98.6821 96.3459 
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  Fig 13: Cumulative percentage drug release profile of F1,F2,F3 
Dissolution profile (% drug release) of formulations F4, F5, F6. 
Table 18: In-vitro dissolution data of Formulation F4, F5, F6 
S.No MEDIUM TIME(hrs) Cumulative % drug release of F4 F5 F6 
1 
0.1N HCl 
0 0.00 0.00 0.00 
2 0.15 9.3620 11.8586 11.2344 
3 0.30 18.7241 19.3482 19.9724 
4 0.45 20.0134 20.5965 20.3498 
5 1 20.9986 21.8448 22.3994 
6 2 23.5893 23.6735 23.9182 
7 
pH 6.8 
phosphate 
buffer 
4 26.8345 34.2164 29.7834 
8 6 33.7256 40.1671 37.8203 
9 8 39.8345 45.1260 43.8745 
10 12 60.8345 58.5150 57.0274 
11 24 88.7643 86.7643 84.7972 
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 Fig 14: Cumulative percentage drug release profile of F4, F5, F6 
Dissolution profile (% drug release) of formulations F7, F8, F9. 
Table 19: In-vitro dissolution data of Formulation F7, F8, F9 
S.No MEDIUM TIME(hrs) Cumulative % drug release of F7 F8 F9 
1 
0.1N HCl 
0 0.00 0.00 0.00 
2 0.15 11.8586 12.4827 11.8586 
3 0.30 19.3482 18.1 19.9724 
4 0.45 20.7459 20.5965 20.8934 
5 1 22.6823 21.8934 21.8347 
6 2 23.9823 23.8469 24.7823 
7 
pH 6.8 
phosphate 
buffer 
4 28.8456 27.7823 29.7845 
8 6 35.8934 34.8349 36.8934 
9 8 42.8934 40.8348 44.8736 
10 12 65.8349 65.8934 69.7356 
11 24 99.4739 94.2191 96.6986 
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Fig 15: Cumulative percentage drug release profile of F7, F8, F9 
 
 
In-vitro dissolution studies of all the formulation of Sumatriptan succinate bilayer 
tablets were carried out in 0.1 N HCl for first two hours and in pH6.8 phosphate buffer for 
next upto 24 hours. The study was performed for 24 hrs and cumulative drug release was 
calculated at different time interval. 
The formulation F1, F2 and F3 showed the drug release 95.7068,98.6821,96.3459 
upto 24 hrs but F4, F5 and F6 showed the drug release 88.7643, 86.7643, 84.7972 upto 24    
hrs which is having high retarding capacity and due to this the polymer content is        
decreased in the next three formulations and F7 showed the drug release 99.4739 upto    
24hrs and F8,F9 showed the drug release 94.2191, 96.6986% up to 24hours.  Hence drug 
released from F7 formulation shows good retarding capacity and it is considered as the      
best formulation. 
Drug release from all the bilayer tablet formulations followed diffusion control 
mechanism with R2 value nearer to one. 
0
20
40
60
80
100
120
0 5 10 15 20 25 30
C
u
m
u
la
ti
v
e
 %
 o
f 
d
ru
g
 r
e
le
a
se
Time in hours
f7
f8
f9
RESULTS AND DISCUSSION                                                                                      CHAPTER-9 
 
 
ADHIPARASAKTHI COLLEGE OF PHARMACY  105 
 
9.4.2.2 Kinetics of In-vitro Drug Release:  
 The drug diffusion through most type of polymeric system is often best described      
by Fickian diffusion (diffusion exponent, n=0.5), but other process in addition to diffusion 
are important. There is also a relaxation of the polymer chain, which influences the drug 
release mechanism. This process is described as non- fickian or anomalous diffusion     
(n=0.5-1.0).  Release from initially dry, hydrophilic glassy polymer that swell when added     
to water and become rubbery, show anomalous diffusion as a result of the rearrangement     
of macromolecular chain. The thermodynamics state of the polymer and penetrant 
concentration are responsible for the different type of the diffusion. A third class of     
diffusion is case-II diffusion (n=1), which is a special case of non- Fickian diffusion. To 
obtain kinetic parameter of dissolution profile, data were fitted to different kinetic models. 
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Table 20: Different Kinetic models for Formulations F1-F9 
Code 
Zero order  First order Higuchi Korsemayer’s-Peppas 
Best 
fit 
model R2 K0 (mg/h−1) R
2
 
K1 
(h-1) 
R2 
K  
(mg 
h−1/2) 
R2 n 
F1 0.9676 0.0166 0.9684 0.0002 0.9742 0.0694 0.9885 0.4032 Peppas 
F2 0.9738 0.0164 0.9746 0.0002 0.9778 0.0686 0.9911 0.3970 Peppas 
F3 0.9335 0.0162 0.9344 0.0002 0.9745 0.0678 0.9913 0.3775 Peppas 
F4 0.9277 0.0136 0.9285 0.0001 0.9681 0.0567 0.9834 0.3596 Peppas 
F5 0.9604 0.0137 0.9612 0.0001 0.9719 0.0569 0.9738 0.3475 Peppas 
F6 0.9703 0.0138 0.9711 0.0001 0.9722 0.0573 0.9711 0.3482 Matrix 
F7 0.9726 0.0169 0.9736 0.0002 0.9602 0.0718 0.9893 0.4051 Peppas 
F8 0.9481 0.0293 0.9485 0.0003 0.9911 0.0861 0.9889 0.4462 Matrix 
F9 0.8343 0.0296 0.8347 0.0003 0.9882 0.0870 0.9855 0.4476 Matrix 
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Fig 16: Peppas plot of formulation F1 
 
 
Fig 17: Peppas plot of formulation F2 
 
 
 
Fig 18: Peppas plot of formulation F3 
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Fig 19: Peppas plot of formulation F4 
 
 
 
Fig 20: Peppas plot of formulation F5 
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Fig 21: Matrix plot of formulation F6 
 
 
 
 
 
Fig 22: Peppas plot of formulation F7 
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Fig 23: Matrix plot of formulation F8 
 
 
 
 
Fig 24: Matrix plot of formulation F9 
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 The data obtained from invitro dissolution studies were fitted to zero order, first     
order, Higuchi, korsmeyers-peppas equation. To confirm the exact mechanism of the drug 
release korsmeyer and peppas equation superposes two apparently independent mechanism    
of drug transport, Fickian diffusion and a case-II transport, for the description of drug     
release from a swelling polymer. 
9.5 STABILITY STUDIES 
 From the results it was found that formulation F7 is the best formulation amongst the      
9 formulations. Thus formulation F7 was selected for stability studies.  
 9.5.1 Stability studies at the end of First month (30 days): 
9.5.1.1 Hardness:  
 The hardness of tablet after one month of stability studies was studied. The results 
are within the limits. The data is shown in Table 21. 
Table 21: Hardness of formulation F1 at the end of 1 month of stability 
                               
 
 
 
All the values are expressed as a mean ± SD., n = 6 
 
9.5.1.2 Drug Content :  
  The Percentage drug content of tablet after one month of stability studies was 
studied. The results are within the official limits. The data is shown in Table 22. 
S. No. Formulation Hardness (kg/cm2) 
1. F7 6.7±1.6 
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 Table 22: Drug content of formulation F7 at the end of 1 month of stability 
S. No. Formulation Percentage drug content 
1. F7 99.20 ±1.4 
All the values are expressed as a mean ± SD., n = 3 
9.5.1.3 In-vitro dissolution study:  
  The Cumulative percentage drug release from F7 tablet after one month of    
stability was studied. The data is shown in Table 23.   
Table 23: In-vitro dissolution data of formulation F7 at the end of 1 month of stability 
S.No TIME(hrs) 
Cumulative % drug 
release of F7 
1 0.15 11.7210 
2 0.30 18.7254 
3 0.45 20.26514 
4 1 22.3561 
5 2 23.0689 
6 4 27.1805 
7 6 34.0239 
8 8 42.1269 
9 12 65.0376 
10 24 99.0526 
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 Fig 25: In-vitro dissolution profile of formulation F7 at the end of 1 month of stability 
9.5.2 Stability studies at the end of Second month (60 days): 
9.5.2.1 Hardness:  
 The hardness of tablet after Two months of stability studies was studied. The     
results are within the limits. The data is shown in Table 24. 
     Table 24: Hardness of formulation F7 at the end of 2 months of stability 
S. No. Formulation Hardness (kg/cm2) 
1. F7 6.7±0.3  
       All the values are expressed as a mean ± SD., n = 6 
9.5.2.2 Drug content:  
  The Percentage drug content of tablet after Two months of stability studies was 
studied. The results are within the official limits. The data is shown in Table 25. 
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Table 25: Drug content of formulation F7 at the end of 2 months of stability 
S. No. Formulation Percentage drug content 
1. F1 99.08 ±0.60 
      All the values are expressed as a mean ± SD., n = 3 
9.5.2.3 In-vitro dissolution study:  
  The Cumulative Percentage Drug Release from F7  tablet after Two months of 
stability was studied. The data is shown in Table 26. 
Table 26: In-vitro dissolution data of formulation F7 at the end of 2 months of  
stability 
S.No TIME(hrs) 
Cumulative % drug 
release of F7 
1 0.15 10.8934 
2 0.30 18.0657 
3 0.45 19.8624 
4 1 22.0364 
5 2 22.9248 
6 4 26.8649 
7 6 33.9214 
8 8 41.8624 
9 12 64.7964 
10 24 98.3269 
 
RESULTS AND DISCUSSION                                                                                      CHAPTER-9 
 
 
ADHIPARASAKTHI COLLEGE OF PHARMACY  115 
 
 
Fig 26: In-vitro dissolution profile of formulation F7 at the end of 2 months of 
stability 
9.5.3 Stability studies at the end of Third month (90 days): 
9.5.3.1 Hardness:  
 The hardness of tablet after Third months of stability studies was studied. The    
results are within the limits. The data is shown in Table 27. 
Table 27: Hardness of formulation F7 at the end of 3 months of stability 
S. No. Formulation Hardness (kg/cm2) 
1. F7 6.6±1.1 
       All the values are expressed as a mean ± SD., n = 6 
9.5.3.2 Drug content:  
  The Percentage drug content of tablet after Third month of stability studies was 
studied. The results are within the official limits. The data is shown in Table 28. 
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Table 28: Drug content of formulation F7 at the end of 3 months of stability 
S. No. Formulation Percentage drug content 
1. F7 98.7±0.8 
     All the values are expressed as a mean ± SD., n = 3 
9.5.3.3 In-vitro dissolution study:  
  The Cumulative percentage drug release from F7 tablet after Three months of 
stability was studied. The data is shown in Table 29. 
 
Table 29: In-vitro dissolution data of formulation F7 at the end of 3 months of      
stability 
S. No TIME(hrs) 
Cumulative % drug 
release of F7 
1 0.15 10.2648 
2 0.30 17.9561 
3 0.45 19.1359 
4 1 21.9624 
5 2 22.3219 
6 4 26.0364 
7 6 33.0934 
8 8 40.9632 
9 12 64.0329 
10 24 98.1298 
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Fig 27: In-vitro dissolution profile of formulation F7 at the end of 3 months of  
stability 
 
 
 
Fig 28: Comparison of drug content for formulation F7 with initial and different 
periods of stability 
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Fig.29 Comparison of cumulative percentage drug released at the end of 24 hours for 
formulation F7 with initial and different periods of stability 
 
No statistically significant differences were observed in Hardness, percentage drug 
content and cumulative percentage drug release in optimized formulation at the end of      
three months of stability studies. 
So it can be concluded that the formulation F7 is stable for short term storage    
conditions. 
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10. SUMMARY AND CONCLUSIONS 
The formulation development and in-vitro evaluation of bilayer drug delivery      
system of Sumatriptan succinate tablets was performed in the present study. 
The bilayer tablets of sumatriptan succinate were prepared by using polymers like 
guar gum, xanthan gum, sodium alginate for the treatment of migraine. The dissolution     
study of F7 bilayer tablets containing guar gum and xanthan gum was concluded the best 
formulation among other formulations, which showing the most desired drug release. It     
will be considered as optimized formulation. 
The optimized formulation F7 was subjected for stability studies, the formulation    
was found to be stable in short term stability study. 
Preformulation study was carried out for powder blends, it was evaluated to    
determine the flow characteristics by angle of repose, bulk density, tapped density, carr’s 
index and Hausner’s ratio. The data obtained from these studies indicated that the powder 
blends had good flow properties. 
The tablets were prepared with different ratios of polymers by direct compression    
and wet granulation technique. The formulated tablets were evaluated for physical 
characterization like thickness, hardness, friability, weight variation and drug content. All    
the physical parameters of prepared tablets comply with IP specifications. 
Evaluation studies of all formulations showed that the drug content, weight     
variation and friability as per the standards given in IP. The hardness of all formulations     
was within the limits. 
The in-vitro dissolution studies closely indicate that among nine formulations the 
formulation F7 was found to be the best with good retard of drug release. 
The regression correlation co-efficient value was concluded in kinetics modeling of 
drug dissolution profile for all formulations. The formulation F7 having R2 value lies    
between 0.5 to 1.0. Hence it is concluded that formulation F7 following peppas drug     
release. 
From the stability data, it can be concluded that there was no significant changes in 
any parameters. Hence the formulation F7 is considered to be highly stable formulation. 
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The overall studies indicate that polymers Xanthan gum, Guar gum showed 
satisfactory properties. Among the nine formulations the formulation F7 exhibited      
optimum drugs release profile. Hence, it is concluded that the formulation F7 will be        
useful for bilayer drug release. 
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11. FUTURE PROSPECTS 
In the present work bilayer tablets of Sumatriptan succinate were formulated using 
natural polymers by direct compression and wet granulation methods. In this work only 
physicochemical characterization, formulation and in-vitro evaluation of bilayer tablets of 
Sumatriptan succinate was done. Along with in-vitro release study in-vivo release      
behaviour of drug is also important. So in future in-vivo release study using different      
models are required to set the in-vitro in-vivo correlation which is necessary for      
development of successful formulation and also long term stability studies are necessary. 
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